<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pituitary</journal-id><journal-id journal-id-type="iso-abbrev">Pituitary</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Pituitary</journal-title></journal-title-group><issn pub-type="ppub">1386-341X</issn><issn pub-type="epub">1573-7403</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474669</article-id><article-id pub-id-type="pmcid-ver">PMC12474669.1</article-id><article-id pub-id-type="pmcaid">12474669</article-id><article-id pub-id-type="pmcaiid">12474669</article-id><article-id pub-id-type="pmid">41006930</article-id><article-id pub-id-type="doi">10.1007/s11102-025-01578-1</article-id><article-id pub-id-type="publisher-id">1578</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of proton therapy and photon therapy for patients with craniopharyngioma: a systematic review and meta&#8209;analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Pan</surname><given-names initials="LS">Lai-Sheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jing</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiong</surname><given-names initials="YT">Yu-Tong</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhan</surname><given-names initials="JB">Jin-Bo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="QY">Qi-Yuan</given-names></name><address><email>qywang23@cmu.edu.cn</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hong</surname><given-names initials="T">Tao</given-names></name><address><email>ndyfy00567@ncu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042v6xz23</institution-id><institution-id institution-id-type="GRID">grid.260463.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2182 8825</institution-id><institution>Jiangxi Key Laboratory of Neurological Diseases, Department of Neurosurgery, the First Affiliated Hospital, Jiangxi Medical College, </institution><institution>Nanchang University, </institution></institution-wrap>17 Yong Wai Zheng Street, Nanchang, 330006 Jiangxi China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042v6xz23</institution-id><institution-id institution-id-type="GRID">grid.260463.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2182 8825</institution-id><institution>The First Clinical Medical College, </institution><institution>Nanchang University, </institution></institution-wrap>Nanchang, Jiangxi China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/042v6xz23</institution-id><institution-id institution-id-type="GRID">grid.260463.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2182 8825</institution-id><institution>Department of Radiation Oncology, the First Affiliated Hospital, Jiangxi Medical College, </institution><institution>Nanchang University, </institution></institution-wrap>Nanchang, Jiangxi China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01n3v7c44</institution-id><institution-id institution-id-type="GRID">grid.452816.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 9522</institution-id><institution>Department of Radiology, </institution><institution>the People&#8217;s Hospital of China Medical University, the People&#8217;s Hospital of Liaoning Province, </institution></institution-wrap>33 Wenyi Road, Shenhe District, Shenyang, 110067 Jiangxi China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>28</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">497685</issue-id><elocation-id>103</elocation-id><history><date date-type="received"><day>18</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="11102_2025_Article_1578.pdf"/><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">According to existing epidemiological evidence, whether proton therapy is more efficacious and safe than photon therapy in the treatment of craniopharyngioma (CP) remains controversial. This study aimed to evaluate whether proton therapy exhibits better efficacy and safety in terms of survival outcomes and toxic effects than photon therapy.</p></sec><sec><title>Methods</title><p id="Par2">An extensive search of pertinent articles published between 1990 and February 2025 was performed in the following four databases: PubMed, Web of Science, Embase, and the Cochrane Library. Original studies investigating the efficacy and safety of proton or photon therapy in patients with CP were included. This meta-analysis is reported following the PRISMA reporting guidelines, and data were pooled using a random effects model.</p></sec><sec><title>Results</title><p id="Par3">A total of 43 studies on 2784 patients were included in the meta-analysis. The pooled analysis favored proton therapy over photon therapy in terms of 3-year progression-free survival, 5-year progression-free survival, 5-year overall survival, 3-year local control and 5-year local control but not 3-year overall survival. In the safety analysis, compared with photon therapy, proton therapy was associated with reduced probabilities of visual, neurological, cognitive, and other miscellaneous toxicities, whereas the opposite trend was observed for endocrine toxicity. Subgroup analysis indicated that conventional radiation therapy had superior survival outcomes than stereotactic radiosurgery.</p></sec><sec><title>Conclusions</title><p id="Par4">Compared with photon therapy, proton therapy may be associated with improved survival outcomes and reduced incidence of toxic effects in CP patients. Conventional radiation therapy appears to be more effective than stereotactic radiosurgery.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s11102-025-01578-1.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Craniopharyngioma</kwd><kwd>Radiotherapy</kwd><kwd>Proton therapy</kwd><kwd>Systematic review</kwd><kwd>Meta-analysis</kwd></kwd-group><funding-group><award-group><funding-source><institution>Postgraduate Project of Jiangxi Society for Science Education</institution></funding-source><award-id>2025KXJYS256</award-id><principal-award-recipient><name name-style="western"><surname>Pan</surname><given-names>Lai-Sheng</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82360611</award-id><principal-award-recipient><name name-style="western"><surname>Hong</surname><given-names>Tao</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Science and Technology Plan Project of Health Commission of Jiangxi Province</institution></funding-source><award-id>2023ZD002</award-id><principal-award-recipient><name name-style="western"><surname>Hong</surname><given-names>Tao</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Craniopharyngiomas (CPs) are among the most common destructive lesions of the hypothalamus and pituitary gland, with a global incidence of 1.34 per million [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Despite being generally classified as low histological grade (WHO grade I) [<xref ref-type="bibr" rid="CR3">3</xref>], the particular positioning of CPs and their adhesions to adjacent critical neurovascular structures make definitive treatment challenging. Treatment may involve surgery alone, radiation alone, or, more commonly, a combination of both modalities.</p><p id="Par6">Surgery is the most effective curative treatment method for CP, as gross total resection (GTR) is the primary prognostic factor; however, GTR is frequently infeasible because of the risk of damaging critical tissue structures, especially the hypothalamus [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Consequently, radiotherapy (RT) after surgery is essential to improve patient prognosis [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. RT alone may also be an appropriate option for patients who cannot undergo radical surgical resection or who do not require surgical intervention to alleviate symptoms [<xref ref-type="bibr" rid="CR8">8</xref>]. RT mainly utilizes protons or photons, and advances in RT technology have improved the precision of treatment and reduced exposure to normal brain tissue. Theoretically, compared with photon therapy, proton therapy can deliver higher doses of energy to the target area while reducing the impact on surrounding normal tissue owing to the Bragg peak effect [<xref ref-type="bibr" rid="CR9">9</xref>]. Moreover, the greater relative biological effectiveness (RBE) [<xref ref-type="bibr" rid="CR10">10</xref>] of proton therapy may further improve survival outcomes. However, these theoretical advantages have yet to be substantiated through comprehensive evaluation in high-level evidence studies.</p><p id="Par7">Recently, a meta-analysis investigated the efficacy and safety profiles of proton therapy versus photon therapy in childhood-onset CP patients [<xref ref-type="bibr" rid="CR11">11</xref>]. However, the study had notable limitations, as direct comparisons of pooled outcomes were not performed to facilitate definitive conclusions and the toxicity assessment was restricted solely to vasculopathy-related complications. Given the inherent rarity of CP, the prolonged timeline and multi-institutional coordination required for clinical trials, coupled with the high costs associated with current proton therapy facilities, conducting randomized controlled trials (RCTs) to systematically compare clinical outcomes between these two radiotherapy modalities is difficult to conduct. The present study addresses these gaps by implementing a systematic review methodology that comprehensively evaluates critical clinical endpoints, including overall survival (OS), progression-free survival (PFS), local control rates (LCRs) and treatment-related toxic effects, in CP patients receiving either proton or photon radiotherapy. The present study provides the first comprehensive systematic review and meta-analysis comparing therapeutic efficacy and safety profiles between proton and photon radiotherapy in mixed-age CP cohorts.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study design</title><p id="Par8">The present study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines [<xref ref-type="bibr" rid="CR12">12</xref>]. A protocol was developed to establish the inclusion criteria, search strategy, target outcomes, and analysis plan. On August 27, 2024, the study was prospectively registered with PROSPERO (CRD42021293449).</p></sec><sec id="Sec4"><title>Search strategy</title><p id="Par9">To identify papers suitable for inclusion in the present study, we performed an extensive search of pertinent articles published between 1990 and July 2024 in the following four databases: PubMed, Web of Science, Embase, and the Cochrane Library. We also conducted a forward search of the included studies until February 2025. The databases were queried by employing a combination of Medical Subject Headings and free-text keywords. The detailed search strategies are provided in the Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>.</p></sec><sec id="Sec6"><title>Inclusion and exclusion criteria</title><p id="Par10">The inclusion criteria for the studies were as follows: (1) at least 10 patients with CP; (2) treatment with photon therapy or proton therapy; (3) description of essential outcome indicators (survival outcomes and toxic effects); (4) original studies in English (i.e., observational studies, case series, RCTs, non-RCTs or single-arm tests). The exclusion criteria for the studies were as follows: (1) studies prior to 1990 (to ensure the incorporation of research utilizing modern radiation therapy techniques); (2) devoid of full text; (3) editorials, letters, comments, conference abstracts, case reports, reviews, and meta-analyses.</p></sec><sec id="Sec7"><title>Data extraction</title><p id="Par11">Each of the two investigators (J.Z. and YT.X.) separately extracted all pertinent data from the research. In cases of dispute on the inclusion of a study, a third investigator (LS.P.) had the ultimate authority to make the final recommendation. The following essential data was collected from the included studies: authors, publication year, study area, follow-up duration, patient count, and patient characteristics (i.e., age, sex, radiation technique, prescribed dose, and tumor features). Outcome data was collected with regard to two aspects, namely, efficacy and safety. The effectiveness of the two radiation therapies was evaluated using 3- and 5-year OS, PFS and LCR as quantitative measures. The safety indices included visual, endocrine, neurological, cognitive, and other miscellaneous toxic effects after proton or photon therapy.</p></sec><sec id="Sec8"><title>Quality assessment</title><p id="Par12">As this systematic review and meta-analysis included non-comparative studies, the Newcastle&#8210;Ottawa scale (NOS) [<xref ref-type="bibr" rid="CR13">13</xref>] was used to evaluate the quality of the studies. Two authors (J.Z. and YT.X.) separately completed the work, with a third researcher (LS.P.) resolving any disagreements. The NOS comprises nine components categorized into three major groups as follows: outcomes, comparability, and selection. A project is awarded a score of 1 point if the research fulfills the corresponding criteria. Comprehensive assessment outcomes are provided in the Supplementary Table S2.</p></sec><sec id="Sec10"><title>Statistical analysis</title><p id="Par13">The event rates of outcome (the percentage of patients who experienced outcomes of interest) from the included cohorts were computed. The event rates were aggregated using the DerSimonian and Laird random-effect models [<xref ref-type="bibr" rid="CR14">14</xref>]. Additionally, double-arcsine transformations were applied to the distribution type of a single rate if it did not follow a normal distribution to increase the dependability of the combined data [<xref ref-type="bibr" rid="CR15">15</xref>]. Quantitative heterogeneity was assessed using I<sup>2</sup>&#160;and Q statistics. Values exceeding 50% were considered to indicate moderate-to-high heterogeneity [<xref ref-type="bibr" rid="CR16">16</xref>]. Because the dose of stereotactic radiosurgery (SRS) is different from that of other methods in photon therapy, the doses of photon therapy and proton therapy were compared after excluding SRS, and subgroup analyses were conducted to compare the survival results of proton therapy with those of SRS and non-SRS. Simultaneously, age groups were categorized to evaluate the efficacy and safety of proton therapy versus photon therapy in children and adults. Potential publication bias was assessed through visual inspection of funnel plot symmetry and the Egger regression asymmetry test [<xref ref-type="bibr" rid="CR17">17</xref>]. All analyses were carried out using SPSS (version 20.0) and Stata (version 17.0). A <italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.05 was considered significant.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Study selection</title><p id="Par14">Upon an exhaustive search of four databases, 6,150 studies were identified. After the initial screening (excluding duplicate, non-English, and pre-1990 research), 2,965 articles were retained. Upon reading the abstracts and titles of these papers, 156 were left available for analysis of the entire texts according to the inclusion criteria. Ultimately, 43 studies met the inclusion criteria and were included in this analysis (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Among them, 4 studies [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>] conducted a direct comparison between proton and photon therapy for the treatment of CPs. Among the remaining 39 uncontrolled observational studies, 10 studies [<xref ref-type="bibr" rid="CR22">22</xref>&#8211;<xref ref-type="bibr" rid="CR31">31</xref>] described the effects of proton therapy, whereas 29 studies [<xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR60">60</xref>] described the effects of photon therapy. The features of the included studies are shown in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par15">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flowchart of the study screening and evaluation process</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e370" position="float" orientation="portrait" xlink:href="11102_2025_1578_Fig1_HTML.jpg"/></fig>
</p><p id="Par16">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>General characteristic of craniopharyngioma studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Study</th><th align="left" colspan="1" rowspan="1">Region</th><th align="left" colspan="1" rowspan="1">Study<break/>Period</th><th align="left" colspan="1" rowspan="1">Radiation<break/>(patients, <italic toggle="yes">n</italic>)</th><th align="left" colspan="1" rowspan="1">Age (years)</th><th align="left" colspan="1" rowspan="1">Men (<italic toggle="yes">n</italic>)/<break/>Women (<italic toggle="yes">n</italic>)</th><th align="left" colspan="1" rowspan="1">Tumor size<break/>(cm&#179;)</th><th align="left" colspan="1" rowspan="1">Tumor histology</th><th align="left" colspan="1" rowspan="1">Dose<break/>(Gy RBE)</th><th align="left" colspan="1" rowspan="1">Follow-up time<break/>(years)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><p>Friedrich,</p><p>2022</p></td><td align="left" colspan="1" rowspan="1">Germany</td><td align="left" colspan="1" rowspan="1">2007&#8211;2019</td><td align="left" colspan="1" rowspan="1"><p>Photon therapy (35)</p><p>Proton therapy (64)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>XRT 10.0 (5.6&#8211;17.2)</p><p>Proton therapy 10.9 (2.5&#8211;20.8)</p></td><td align="left" colspan="1" rowspan="1"><p>XRT 15/20</p><p>Proton therapy 34/30</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range) XRT</p><p>23.0 (0.9&#8211;107.2)</p><p>Proton therapy</p><p>22.1 (0.1&#8211;286.3)</p></td><td align="left" colspan="1" rowspan="1">ACP (100%)</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>XRT</p><p>54.0 (50.4&#8211;54.0)</p><p>Proton therapy</p><p>54.0 (50.4&#8211;54.0)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>XRT 8.0 (2.4&#8211;14.7)</p><p>Proton therapy 5.2 (0.9&#8211;14.1)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Merchant,</p><p>2023</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1"><p>2011&#8211;2016/</p><p>1998&#8211;2013</p></td><td align="left" colspan="1" rowspan="1"><p>Photon therapy</p><p>(101)</p><p>Proton therapy</p><p>(94)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (IQR)</p><p>Photon therapy</p><p>8.98 (6.31&#8211;13.02)</p><p>Proton therapy</p><p>9.39 (6.39&#8211;13.38)</p></td><td align="left" colspan="1" rowspan="1"><p>Photon therapy</p><p>55/46</p><p>Proton therapy</p><p>45/49</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (IQR) Photon therapy 13.25 (9.43&#8211;16.65)</p><p>Proton therapy</p><p>7.62 (6.48&#8211;8.54)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Bishop,</p><p>2014</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">1996&#8201;&#8722;&#8201;2012</td><td align="left" colspan="1" rowspan="1"><p>Proton therapy (21)</p><p>IMRT (31)</p></td><td align="left" colspan="1" rowspan="1"><p>Median</p><p>Proton therapy</p><p>9.1</p><p>IMRT</p><p>8.8</p></td><td align="left" colspan="1" rowspan="1"><p>Proton therapy 9/12</p><p>IMRT</p><p>14/17</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Proton therapy 50.4</p><p>IMRT 50.4</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>Proton therapy</p><p>2.76 (0.88&#8211;5.47)</p><p>IMRT</p><p>8.84 (0.74&#8211;15.44)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Ravindra,</p><p>2021</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">1997&#8211;2018</td><td align="left" colspan="1" rowspan="1"><p>IMRT (14)</p><p>Proton therapy (18)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>IMRT 7 (5&#8211;10) Proton therapy</p><p>12 (6&#8211;16)</p></td><td align="left" colspan="1" rowspan="1"><p>IMRT 6/8</p><p>Proton therapy 10/8</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median(95% CI)</p><p>IMRT</p><p>5.91 (3.24&#8211;8.91)</p><p>Proton therapy</p><p>3.95 (1.91&#8211;7.03)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Beddok,</p><p>2023</p></td><td align="left" colspan="1" rowspan="1">France</td><td align="left" colspan="1" rowspan="1">2006&#8211;2008</td><td align="left" colspan="1" rowspan="1"><p>Proton therapy</p><p>(91)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (IQR)</p><p>37 (26&#8211;51)</p></td><td align="left" colspan="1" rowspan="1">52/39</td><td align="left" colspan="1" rowspan="1"><p>Median (IQR)</p><p>13.7 (9.4&#8211;22.4)</p></td><td align="left" colspan="1" rowspan="1"><p>ACP (41.8%)</p><p>PCP (13.2%)</p><p>NOS (45%)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Median (range) 3.25 (0.58&#8211;12.25)</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Ajithkumar,</p><p>2018</p></td><td align="left" colspan="1" rowspan="1">Germany</td><td align="left" colspan="1" rowspan="1">2013&#8211;2016</td><td align="left" colspan="1" rowspan="1"><p>Proton therapy</p><p>(18)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>10.2 (5.4&#8211;46.9)</p></td><td align="left" colspan="1" rowspan="1">5/11</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>2.83 (0.77&#8211;5.88)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Rutenberg,</p><p>2020</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">2012&#8211;2018</td><td align="left" colspan="1" rowspan="1"><p>Proton therapy</p><p>(14)</p></td><td align="left" colspan="1" rowspan="1"><p>Median(range)</p><p>28 (22&#8211;53)</p></td><td align="left" colspan="1" rowspan="1">5/9</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>ACP (79%)</p><p>PCP (14%)</p><p>NOS (7%)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>54 (52.2&#8211;54)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>2.22 (0.92&#8211;5.33)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Baldo,</p><p>2022</p></td><td align="left" colspan="1" rowspan="1">Italy</td><td align="left" colspan="1" rowspan="1">2015&#8211;2021</td><td align="left" colspan="1" rowspan="1">Proton therapy 10</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>10.7 (6.1&#8211;16.6)</p></td><td align="left" colspan="1" rowspan="1">6/4</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>2.33 (1.13&#8211;6.48)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Indelicato,</p><p>2017</p></td><td align="left" colspan="1" rowspan="1">UK</td><td align="left" colspan="1" rowspan="1">2008&#8211;2016</td><td align="left" colspan="1" rowspan="1"><p>Proton therapy</p><p>42</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>7 (1&#8211;19)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>54 (52.2&#8211;54)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>2.6 (0.2&#8211;7.6)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Tran,</p><p>2020</p></td><td align="left" colspan="1" rowspan="1">Switzerland</td><td align="left" colspan="1" rowspan="1">1999&#8211;2017</td><td align="left" colspan="1" rowspan="1">Proton therapy 22</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>9.9 (2.5&#8211;18.2)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Median (range) 54.0 (18-64.8)</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>4.25 (0.33&#8211;18.5)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Luu,</p><p>2006</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">1991&#8211;2000</td><td align="left" colspan="1" rowspan="1">Proton therapy 16</td><td align="left" colspan="1" rowspan="1">Range 7&#8211;34</td><td align="left" colspan="1" rowspan="1">10/6</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Range</p><p>50.4&#8211;59.4</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>5.02 (1&#8211;10.08)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Scher,</p><p>2021</p></td><td align="left" colspan="1" rowspan="1">France</td><td align="left" colspan="1" rowspan="1">2006&#8211;2018</td><td align="left" colspan="1" rowspan="1">Proton therapy 93</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>36.5 (18&#8211;82)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>54 (52.2&#8201;&#8722;&#8201;54)</p></td><td align="left" colspan="1" rowspan="1">Median 3.08</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Bischoff,</p><p>2024</p></td><td align="left" colspan="1" rowspan="1">Germany</td><td align="left" colspan="1" rowspan="1">2006&#8211;2018</td><td align="left" colspan="1" rowspan="1">Proton therapy 74</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>9.21 (3.38&#8211;17.52)</p></td><td align="left" colspan="1" rowspan="1">32/42</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>17.64 (3.07-300.59)</p></td><td align="left" colspan="1" rowspan="1"><p>ACP (91.9%)</p><p>NOS (8.1%)</p></td><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>4.3 (0.8&#8211;14.7)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Jimenez,</p><p>2021</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">2002&#8211;2018</td><td align="left" colspan="1" rowspan="1">Proton therapy 77</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>9.6 (2.3&#8211;20.5)</p></td><td align="left" colspan="1" rowspan="1">41/36</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>52.2 (45&#8211;54)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>4.8 (0.8&#8211;15.6)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Combs,</p><p>2007</p></td><td align="left" colspan="1" rowspan="1">Germany</td><td align="left" colspan="1" rowspan="1">1989&#8211;2006</td><td align="left" colspan="1" rowspan="1">FSRT 40</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>41 (6&#8211;70)</p></td><td align="left" colspan="1" rowspan="1">16/24</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>52.2 (50.4&#8211;56)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>8.17 (0.25&#8211;27.17)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Samanci,</p><p>2023</p></td><td align="left" colspan="1" rowspan="1">Turkey</td><td align="left" colspan="1" rowspan="1">2017&#8211;2021</td><td align="left" colspan="1" rowspan="1">GKRS 24</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>38.5 (3&#8211;66)</p></td><td align="left" colspan="1" rowspan="1">9/15</td><td align="left" colspan="1" rowspan="1"><p>Mean&#8201;&#177;&#8201;SD</p><p>2.4&#8201;&#177;&#8201;1.93</p></td><td align="left" colspan="1" rowspan="1"><p>ACP (79.2%)</p><p>PCP (20.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>20 (18&#8211;25)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>1.96 (1-4.17)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Greenfield,</p><p>2015</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">1996&#8211;2006</td><td align="left" colspan="1" rowspan="1">IMRT 24</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>8.2 (3.2&#8211;18.2)</p></td><td align="left" colspan="1" rowspan="1">12/12</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>50.4 (49.8&#8211;54)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>8.9 (0.4&#8211;15.4)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Harrabi,</p><p>2014</p></td><td align="left" colspan="1" rowspan="1">Germany</td><td align="left" colspan="1" rowspan="1">1989&#8211;2012</td><td align="left" colspan="1" rowspan="1">FSRT 55</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>37 (6&#8211;70)</p></td><td align="left" colspan="1" rowspan="1">27/28</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>52.2 (50&#8211;57.6)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>10.67 (0.17&#8211;23)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Hashizume,</p><p>2010</p></td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">2006&#8211;2009</td><td align="left" colspan="1" rowspan="1">SRT 10</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>56.5 (10&#8211;74)</p></td><td align="left" colspan="1" rowspan="1">6/4</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>7.9 (1.1&#8211;21)</p></td><td align="left" colspan="1" rowspan="1"><p>ACP (70%)</p><p>PCP (30%)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>33 (30&#8211;39)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>2.125 (0.75&#8211;3)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Lee,</p><p>2014</p></td><td align="left" colspan="1" rowspan="1">China</td><td align="left" colspan="1" rowspan="1">1993&#8211;2012</td><td align="left" colspan="1" rowspan="1">GKRS 137</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>30.1 (1.5&#8211;84.9)</p></td><td align="left" colspan="1" rowspan="1">56/81</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>(0.2&#8211;28.4)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>12(9.5&#8211;16.0)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>3.81 (0.5&#8211;18.83)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Lopez,</p><p>2019</p></td><td align="left" colspan="1" rowspan="1">Spain</td><td align="left" colspan="1" rowspan="1">2005&#8211;2016</td><td align="left" colspan="1" rowspan="1">FSRT 36</td><td align="left" colspan="1" rowspan="1"><p>Mean (range)</p><p>33 (6&#8211;72)</p></td><td align="left" colspan="1" rowspan="1">12/24</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1"><p>Median</p><p>1.92</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Losa,</p><p>2018</p></td><td align="left" colspan="1" rowspan="1">Italy</td><td align="left" colspan="1" rowspan="1">1994&#8211;2016</td><td align="left" colspan="1" rowspan="1">GKRS 50</td><td align="left" colspan="1" rowspan="1"><p>Mean&#8201;&#177;&#8201;SD</p><p>41.5&#8201;&#177;&#8201;2.8</p></td><td align="left" colspan="1" rowspan="1">29/21</td><td align="left" colspan="1" rowspan="1"><p>Mean</p><p>2.15&#8201;&#177;&#8201;0.3</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Mean</p><p>Single 14.9&#8201;&#177;&#8201;0.6</p><p>Multi 6.9&#8201;&#177;&#8201;0.6</p></td><td align="left" colspan="1" rowspan="1"><p>Mean (range)</p><p>6.22&#8201;&#177;&#8201;0.7 (0.5&#8211;18.92)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Minniti,</p><p>2007</p></td><td align="left" colspan="1" rowspan="1">UK</td><td align="left" colspan="1" rowspan="1">1994&#8211;2003</td><td align="left" colspan="1" rowspan="1">SCRT 39</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>18 (3&#8211;68)</p></td><td align="left" colspan="1" rowspan="1">22/17</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>10.2 (2.05&#8211;35.8)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>3.33 (0.25&#8211;7.33)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Astradsson,</p><p>2017</p></td><td align="left" colspan="1" rowspan="1">Denmark</td><td align="left" colspan="1" rowspan="1">1999&#8211;2015</td><td align="left" colspan="1" rowspan="1">FSRT 16</td><td align="left" colspan="1" rowspan="1"><p>Mean (range)</p><p>52 (17&#8211;71)</p></td><td align="left" colspan="1" rowspan="1">9/7</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>54 (48&#8211;54)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>3.6 (0.7&#8211;13.1)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Pikis,</p><p>2021</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">1989&#8211;2019</td><td align="left" colspan="1" rowspan="1">GKRS 38</td><td align="left" colspan="1" rowspan="1"><p>Mean&#8201;&#177;&#8201;SD</p><p>30.82&#8201;&#177;&#8201;20.45</p></td><td align="left" colspan="1" rowspan="1">24/14</td><td align="left" colspan="1" rowspan="1"><p>Mean&#8201;&#177;&#8201;SD</p><p>5.15&#8201;&#177;&#8201;5.72</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Mean</p><p>13.26&#8201;&#177;&#8201;4.01</p></td><td align="left" colspan="1" rowspan="1"><p>Median radiologic follow-up, (IQR) 3.625 (5.29) </p><p>Median clinical follow-up, (IQR) 3.71 (7.04)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Poiset,</p><p>2024</p></td><td align="left" colspan="1" rowspan="1"><p>USA,</p><p>South Korea</p></td><td align="left" colspan="1" rowspan="1">1999&#8211;2021</td><td align="left" colspan="1" rowspan="1">Photon therapy 81</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>44 (19&#8211;79)</p></td><td align="left" colspan="1" rowspan="1">44/37</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>ACP (55.5%)</p><p>PCP (24.7%)</p><p>NOS (19.8%)</p></td><td align="left" colspan="1" rowspan="1"><p>Range</p><p>FRT 48&#8211;60</p><p>SRS 9&#8211;18</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>6.575(0.08&#8211;22.33)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Shinojima,</p><p>2024</p></td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">2006&#8211;2021</td><td align="left" colspan="1" rowspan="1">SRT 23</td><td align="left" colspan="1" rowspan="1"><p>Mean (range)</p><p>51.6 (11&#8211;79)</p></td><td align="left" colspan="1" rowspan="1">10/13</td><td align="left" colspan="1" rowspan="1"><p>Median 12.9</p><p>Mean 16.1</p><p>Range 0.7&#8211;54.0</p></td><td align="left" colspan="1" rowspan="1"><p>ACP (65.2%)</p><p>PCP (34.8%)</p></td><td align="left" colspan="1" rowspan="1">Mean (range) 44.0 (27&#8211;50.4)</td><td align="left" colspan="1" rowspan="1"><p>Mean 8.625</p><p>Median 7.33</p><p>Range 2.33&#8211;16.67</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Tsugawa,</p><p>2020</p></td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">1999&#8211;2013</td><td align="left" colspan="1" rowspan="1">GKRS 242</td><td align="left" colspan="1" rowspan="1"><p>Mean (range)</p><p>41 (3&#8211;86)</p></td><td align="left" colspan="1" rowspan="1">127/115</td><td align="left" colspan="1" rowspan="1"><p>Mean (range)</p><p>3.1 (0.03&#8211;22.3)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Mean (range)</p><p>11.4 (8-20.4)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>5.12 (0.25-15)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Xu,</p><p>2011</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">1989&#8211;2005</td><td align="left" colspan="1" rowspan="1">GKRS 37</td><td align="left" colspan="1" rowspan="1"><p>Mean 33.2</p><p>Median 36</p><p>Range 4&#8211;78</p></td><td align="left" colspan="1" rowspan="1">21/16</td><td align="left" colspan="1" rowspan="1"><p>Median 1.6</p><p>Mean 3.24</p><p>Range 0.1&#8211;18.6</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Median (range) 14.5 (6&#8211;25)</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>4.17 (0.67&#8211;17.67)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Schulz-</p><p>Ertner,</p><p>2002</p></td><td align="left" colspan="1" rowspan="1">Germany</td><td align="left" colspan="1" rowspan="1">1989&#8211;2001</td><td align="left" colspan="1" rowspan="1">FSRT 26</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>33.5 (5&#8211;57)</p></td><td align="left" colspan="1" rowspan="1">12/14</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>5.2 (0.5&#8211;27.3)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>52.2 (50.0-57.6)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>3.58 (0.58&#8211;11.92)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Ogino,</p><p>2021</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">1988&#8211;2019</td><td align="left" colspan="1" rowspan="1">SRS 53</td><td align="left" colspan="1" rowspan="1"><p>Median(range)</p><p>41(4&#8211;87)</p></td><td align="left" colspan="1" rowspan="1">28/25</td><td align="left" colspan="1" rowspan="1"><p>Median</p><p>0.63</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>12 (9&#8211;25)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>7.17 (0.5&#8211;32.5)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Maranzano,</p><p>2013</p></td><td align="left" colspan="1" rowspan="1">Italy</td><td align="left" colspan="1" rowspan="1">2004&#8211;2010</td><td align="left" colspan="1" rowspan="1">FSRT 17</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>45 (10&#8211;72)</p></td><td align="left" colspan="1" rowspan="1">11/6</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>12 (2&#8211;62)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>3.83 (0.42&#8211;8)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Moon,</p><p>2005</p></td><td align="left" colspan="1" rowspan="1">South Korea</td><td align="left" colspan="1" rowspan="1">1985&#8211;2002</td><td align="left" colspan="1" rowspan="1">Photon therapy 50</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>29 (2&#8211;64)</p></td><td align="left" colspan="1" rowspan="1">32/18</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>ACP (24%)</p><p>PCP (14%)</p><p>Mixed (8%)</p><p>NOS (54%)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>54 (45&#8211;55.8)</p></td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>10.83 (2.33&#8211;19)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Selch,</p><p>2002</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">1996&#8211;2001</td><td align="left" colspan="1" rowspan="1">SRT 16</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>37 (9&#8211;66)</p></td><td align="left" colspan="1" rowspan="1">8/8</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>7.7 (0.7&#8211;62.8)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Median (range) 50.4 (46.4&#8211;50.4)</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>2.33 (0.5-5)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Gupta,</p><p>2024</p></td><td align="left" colspan="1" rowspan="1">India</td><td align="left" colspan="1" rowspan="1">2011&#8211;2019</td><td align="left" colspan="1" rowspan="1">GKRS 36</td><td align="left" colspan="1" rowspan="1"><p>Mean&#8201;&#177;&#8201;SD</p><p>23.91&#8201;&#177;&#8201;13.64</p><p>Median [IQR]</p><p>21.0 [20.0]</p></td><td align="left" colspan="1" rowspan="1">25/11</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Median (range) 12 (11&#8211;15)</td><td align="left" colspan="1" rowspan="1"><p>Mean&#8201;&#177;&#8201;SD</p><p>5.1675&#8201;&#177;&#8201;2.1675</p><p>Median (IQR)</p><p>5.01 (3.77)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Klimo,</p><p>2015</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">1998&#8211;2010</td><td align="left" colspan="1" rowspan="1">CRT 97</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>8.94 (3.2&#8211;17.64)</p></td><td align="left" colspan="1" rowspan="1">52/45</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>9 (0.7&#8211;19.0)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Hasegawa.</p><p>2010</p></td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">1991&#8211;2002</td><td align="left" colspan="1" rowspan="1">GKRS 100</td><td align="left" colspan="1" rowspan="1"><p>Median</p><p>34</p></td><td align="left" colspan="1" rowspan="1">55/45</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>3.3 (0.1&#8211;36.0)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Median (range) 11.4 (9.6&#8211;18)</td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Niranjan,</p><p>2010</p></td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">1988&#8211;2007</td><td align="left" colspan="1" rowspan="1">GKRS 46</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>23.5 (4&#8211;77)</p></td><td align="left" colspan="1" rowspan="1">22/44</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>1 (0.07-8)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Mean 5.18</p><p>Range 1-19.33</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Kobayashi,</p><p>2005</p></td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">GKRS 100</td><td align="left" colspan="1" rowspan="1">Mean 33.6</td><td align="left" colspan="1" rowspan="1">54/46</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>ACP (67%)</p><p>PCP (33%)</p></td><td align="left" colspan="1" rowspan="1">Median 11.5</td><td align="left" colspan="1" rowspan="1"><p>Mean 5.46</p><p>Median 5.25</p><p>Range 0.5-12.33</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Jeon,</p><p>2011</p></td><td align="left" colspan="1" rowspan="1">South Korea</td><td align="left" colspan="1" rowspan="1">1995&#8211;2009</td><td align="left" colspan="1" rowspan="1"><p>GKRS 13</p><p>FRT 34</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Median (range) GKRS</p><p>11 (10&#8211;12)</p><p>FRT</p><p>50.2 (50&#8211;60)</p></td><td align="left" colspan="1" rowspan="1">NA</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Kobayashi,</p><p>2015</p></td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">2004&#8211;2014</td><td align="left" colspan="1" rowspan="1">GKRS 30</td><td align="left" colspan="1" rowspan="1"><p>Mean (range)</p><p>44.7 (6&#8211;86)</p></td><td align="left" colspan="1" rowspan="1">19/11</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Median 11.7</td><td align="left" colspan="1" rowspan="1"><p>Mean 6.66</p><p>Median 7.58</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Dho,</p><p>2018</p></td><td align="left" colspan="1" rowspan="1">South Korea</td><td align="left" colspan="1" rowspan="1">1998&#8211;2016</td><td align="left" colspan="1" rowspan="1">GKRS 35</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>30(7&#8211;68)</p></td><td align="left" colspan="1" rowspan="1">22/13</td><td align="left" colspan="1" rowspan="1"><p>Mean 1.4</p><p>Median 0.4</p><p>Range</p><p>0.07&#8211;10.82</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Median (range) 15(10&#8211;20)</td><td align="left" colspan="1" rowspan="1"><p>Mean 5.99</p><p>Median 5.42</p><p>Range 1.0-18.75</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Iwata,</p><p>2011</p></td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">2000&#8211;2010</td><td align="left" colspan="1" rowspan="1">Cyber-knife 43</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>44 (3&#8211;85)</p></td><td align="left" colspan="1" rowspan="1">21/22</td><td align="left" colspan="1" rowspan="1"><p>Median (range)</p><p>2 (0.09&#8211;20.8)</p></td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1"><p>Mean (range)</p><p>3.33 (1-7.67)</p></td></tr></tbody></table><table-wrap-foot><p>XRT&#8201;=&#8201;x-ray technique, IMRT&#8201;=&#8201;intensity modulated radiation therapy, FSRT&#8201;=&#8201;fractionated stereotactic radiotherapy, GKRS&#8201;=&#8201;Gamma knife radiosurgery, SRS&#8201;=&#8201;stereotactic radiotherapy surgery, SRT&#8201;=&#8201;stereotactic radiation therapy, CRT&#8201;=&#8201;conformal radiation therapy, FSRT&#8201;=&#8201;fractionated stereotaxic radiation therapy, FRT&#8201;=&#8201;fractionated radiotherapy</p><p>ACP&#8201;=&#8201;adamantinomatous craniopharyngioma; PCP&#8201;=&#8201;papillary craniopharyngioma</p><p>NA&#8201;=&#8201;not available; NOS&#8201;=&#8201;not therwise specified</p><p>RBE&#8201;=&#8201;Relative Biological Effectiveness; CI&#8201;=&#8201;Confidence interval; SD&#8201;=&#8201;Standard Deviation</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec13"><title>Baseline characteristics and quality assessment</title><p id="Par17">From the 43 studies, 48 cohorts were identified. Fourteen cohorts were treated with proton therapy (654 patients), whereas 34 cohorts received photon therapy (2,130 patients). Overall, 2,784 patients were included, with a median age of 15.3 years for the proton therapy cohort and 31.5 years for the photon therapy cohort. The median tumor size, radiation dose and proportion of patients with adamantinomatous type were greater in proton cohort than photon cohort, whereas the proportion of males and the median follow-up duration were greater in photon cohort than in proton cohort. Detailed patient characteristics are provided in the Supplementary Table S3.</p><p id="Par18">With regard to quality assessment, the NOS scores indicated that the methodological quality of the included studies was acceptable. Most studies had adequate durations of follow-up, a patient sample that accurately represented the population, a high level of assurance about the outcomes, and few instances of missing data. The morphology of the funnel plot and the statistical results of the Egger test (Supplementary Table S4) revealed no statistically significant publication bias. Nevertheless, significant heterogeneity (I&#178; &gt;50%) was observed in some analyses due to differences in subjects, interventions and study designs, as data were compared across studies not within them.</p></sec><sec id="Sec14"><title>Survival outcomes</title><p id="Par19">The survival outcomes reported in the included studies are listed in the Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>. Sixteen studies investigated the 3-year PFS following radiation for CPs, with 6 reporting on proton therapy and 12 reporting on photon therapy. For 5-year PFS, there were 5 studies and 21 studies in two groups, respectively. The pooled event rate of PFS for photon therapy was significantly lower than that for proton therapy both at 3 years (relative risk [RR] 0.877, 95% CI 0.846&#8211;0.908; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and at 5 years (RR 0.815, 95% CI 0.778&#8211;0.853; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Furthermore, 10 studies were on proton therapy and 16 studies on photon therapy for 3-year OS. Thirty-six studies reported 5-year OS rates, including 7 for proton therapy and 25 for photon therapy. At 5 years of follow-up, the OS rate of patients receiving photon therapy was significantly lower than that of patients receiving proton therapy (RR 0.952, 95% CI 0.935&#8211;0.969; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), but no significant difference was observed at 3 years (RR 0.987, 95% CI 0.971&#8211;1.003; <italic toggle="yes">p</italic>&#8201;=&#8201;0.141; Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). In addition, 8 proton cohorts and 13 photon cohorts were included for 3-year LC, while 7 proton cohorts and 20 photon cohorts were included for 5-year LC. The LC rate of photon therapy was considerably lower than that of proton therapy after both 3 and 5 years of follow-up (RR 0.973, 95% CI 0.946&#8211;1.001; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; RR 0.862, 95% CI 0.824&#8211;0.901; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par20">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Comparison of primary outcomes for proton therapy cohorts and photon therapy cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Cohorts (<italic toggle="yes">n</italic>)</th><th align="left" colspan="1" rowspan="1">Patients (<italic toggle="yes">n</italic>)</th><th align="left" colspan="1" rowspan="1">Event rate (95% CI)</th><th align="left" colspan="1" rowspan="1">I&#178;</th><th align="left" colspan="1" rowspan="1">Relative risk (95% CI)</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">3-year PFS</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">409</td><td align="left" colspan="1" rowspan="1">0.979 (0.946, 0.998)</td><td align="left" colspan="1" rowspan="1">58.2%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">721</td><td align="left" colspan="1" rowspan="1">0.900 (0.826, 0.957)</td><td align="left" colspan="1" rowspan="1">85.4%</td><td align="left" colspan="1" rowspan="1">0.877 (0.846, 0.908)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="7" rowspan="1">5-year PFS</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">282</td><td align="left" colspan="1" rowspan="1">0.933 (0.898, 0.962)</td><td align="left" colspan="1" rowspan="1">0%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">1272</td><td align="left" colspan="1" rowspan="1">0.814 (0.739, 0.879)</td><td align="left" colspan="1" rowspan="1">89.2%</td><td align="left" colspan="1" rowspan="1">0.815 (0.778, 0.853)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="7" rowspan="1">3-year OS</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">539</td><td align="left" colspan="1" rowspan="1">0.996 (0.978, 1.000)</td><td align="left" colspan="1" rowspan="1">47.1%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">783</td><td align="left" colspan="1" rowspan="1">0.986 (0.968, 0.998)</td><td align="left" colspan="1" rowspan="1">38.6%</td><td align="left" colspan="1" rowspan="1">0.987 (0.971, 1.003)</td><td align="left" colspan="1" rowspan="1">0.141</td></tr><tr><td align="left" colspan="7" rowspan="1">5-year OS</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">327</td><td align="left" colspan="1" rowspan="1">0.999 (0.979, 1.000)</td><td align="left" colspan="1" rowspan="1">36.6%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">1386</td><td align="left" colspan="1" rowspan="1">0.955 (0.935, 0.972)</td><td align="left" colspan="1" rowspan="1">48.2%</td><td align="left" colspan="1" rowspan="1">0.952 (0.935, 0.969)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="7" rowspan="1">3-year LC</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">413</td><td align="left" colspan="1" rowspan="1">0.988 (0.964, 1.000)</td><td align="left" colspan="1" rowspan="1">34.1%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">537</td><td align="left" colspan="1" rowspan="1">0.920 (0.869, 0.961)</td><td align="left" colspan="1" rowspan="1">68.2%</td><td align="left" colspan="1" rowspan="1">0.973 (0.946, 1.001)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="7" rowspan="1">5-year LC</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">374</td><td align="left" colspan="1" rowspan="1">0.927 (0.882, 0.963)</td><td align="left" colspan="1" rowspan="1">40.1%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">1005</td><td align="left" colspan="1" rowspan="1">0.818 (0.746, 0.881)</td><td align="left" colspan="1" rowspan="1">85.6%</td><td align="left" colspan="1" rowspan="1">0.862 (0.824, 0.901)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>An I&#178; &#8805; 50% suggests high heterogeneity across studies</p><p>PFS&#8201;=&#8201;progression-free survival; OS&#8201;=&#8201;overall survival; LC&#8201;=&#8201;local control; CI&#8201;=&#8201;confidence interval;</p><p>The <italic toggle="yes">p</italic> value represents the difference between treatments</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec15"><title>Toxic effects</title><p id="Par21">A detailed comparison of the toxic effects resulting from proton therapy and photon therapy is shown in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. The pooled analysis revealed that the likelihood of visual, neurological, cognitive, and other miscellaneous toxicities was lower for those who received proton therapy than for those who received photon therapy (visual: 4.6% vs. 7.8%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.018; neurological: 5.9% vs. 12.4%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.015; cognitive: 5.0% vs. 9.8%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.026; miscellaneous: 7.8% vs. 37.7%; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). In contrast, endocrine toxicity was more likely among those with proton therapy than among those with photon therapy (27.8% vs. 13.7%; <italic toggle="yes">p</italic>&#8201;=&#8201;0.002). The Supplementary Table S5 presents the reported toxic effects by type.</p><p id="Par22">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Comparison of toxic effect event rates for proton therapy and photon therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Event rate (95% CI)</th><th align="left" colspan="1" rowspan="1">I&#178;</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Visual</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">0.046 (0.028, 0.068)</td><td align="left" colspan="1" rowspan="1">0%</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">0.078 (0.049, 0.113)</td><td align="left" colspan="1" rowspan="1">49.1%</td><td align="left" colspan="1" rowspan="1">0.018</td></tr><tr><td align="left" colspan="4" rowspan="1">Endocrine</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">0.278 (0.074, 0.542)</td><td align="left" colspan="1" rowspan="1">85.9%</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">0.137 (0.060, 0.236)</td><td align="left" colspan="1" rowspan="1">90.6%</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="4" rowspan="1">Neurologic</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">0.059 (0.026, 0.102)</td><td align="left" colspan="1" rowspan="1">37.9%</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">0.124 (0.066, 0.196)</td><td align="left" colspan="1" rowspan="1">48.8%</td><td align="left" colspan="1" rowspan="1">0.015</td></tr><tr><td align="left" colspan="4" rowspan="1">Cognitive</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">0.050 (0.008, 0.119)</td><td align="left" colspan="1" rowspan="1">75.2%</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">0.098 (0.012, 0.235)</td><td align="left" colspan="1" rowspan="1">75.7%</td><td align="left" colspan="1" rowspan="1">0.026</td></tr><tr><td align="left" colspan="4" rowspan="1">Miscellaneous</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">0.078 (0.012, 0.181)</td><td align="left" colspan="1" rowspan="1">72.7%</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Photon therapy</td><td align="left" colspan="1" rowspan="1">0.377 (0.250, 0.512)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>An I&#178; &#8805; 50% suggests high heterogeneity across studies</p><p>CI&#8201;=&#8201;confidence interval</p><p>The <italic toggle="yes">p</italic> value represents the difference between treatments</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec16"><title>Subgroup analysis</title><p id="Par23">Initially, subgroup analyses were performed separately for proton therapy and SRS and for proton therapy and non-SRS. Comparison of proton therapy and SRS revealed that patients with CPs who underwent SRS presented substantially worse survival rates than those treated with proton therapy, as evidenced by PFS, OS, and LC metrics (all relative risks exceeded 1, and the corresponding p values were less than 0.05, Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref> and Table&#160;<xref rid="Tab4" ref-type="table">4</xref>) at both the 3-year and 5-year follow-ups. Conversely, comparison of proton therapy and non-SRS revealed no significant difference in 3-year PFS (RR 0.975, 95% CI 0.944&#8211;1.007; <italic toggle="yes">p</italic>&#8201;=&#8201;0.110), 5-year PFS (RR 0.972, 95% CI 0.929&#8211;1.017; <italic toggle="yes">p</italic>&#8201;=&#8201;0.235), 3-year OS (RR 1.006, 95% CI 0.989&#8211;1.023; <italic toggle="yes">p</italic>&#8201;=&#8201;0.539), 5-year OS (RR 0.980, 95% CI 0.961&#8211;1.000; <italic toggle="yes">p</italic>&#8201;=&#8201;0.072), 3-year LC (RR 0.973, 95% CI 0.946&#8211;1.001; <italic toggle="yes">p</italic>&#8201;=&#8201;0.057) or 5-year LC (RR 0.980, 95% CI 0.938&#8211;1.023; <italic toggle="yes">p</italic>&#8201;=&#8201;0.365; Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref> and Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). Furthermore, subgroup analyses by age revealed results nearly equal to those without group assignment (Supplementary Table S6 and Table S7).</p><p id="Par24">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Comparison of primary outcomes for proton therapy cohorts, non-SRS cohorts and SRS cohorts</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Cohorts (<italic toggle="yes">n</italic>)</th><th align="left" colspan="1" rowspan="1">Patients (<italic toggle="yes">n</italic>)</th><th align="left" colspan="1" rowspan="1">Event rate (95% CI)</th><th align="left" colspan="1" rowspan="1">I&#178;</th><th align="left" colspan="1" rowspan="1">Relative risk (95% CI)</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">3-year PFS</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">396/409</td><td align="left" colspan="1" rowspan="1">0.979 (0.946, 0.998)</td><td align="left" colspan="1" rowspan="1">58.2%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-SRS</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">286/303</td><td align="left" colspan="1" rowspan="1">0.960 (0.903, 0.995)</td><td align="left" colspan="1" rowspan="1">67.6%</td><td align="left" colspan="1" rowspan="1">0.975 (0.944, 1.007)</td><td align="left" colspan="1" rowspan="1">0.110</td></tr><tr><td align="left" colspan="1" rowspan="1">SRS</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">326/418</td><td align="left" colspan="1" rowspan="1">0.820 (0.743, 0.888)</td><td align="left" colspan="1" rowspan="1">61.2%</td><td align="left" colspan="1" rowspan="1">0.806 (0.763, 0.850)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="7" rowspan="1">5-year PFS</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">261/282</td><td align="left" colspan="1" rowspan="1">0.933 (0.898, 0.962)</td><td align="left" colspan="1" rowspan="1">0%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-SRS</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">394/438</td><td align="left" colspan="1" rowspan="1">0.911 (0.845, 0.962)</td><td align="left" colspan="1" rowspan="1">73.6%</td><td align="left" colspan="1" rowspan="1">0.972 (0.929, 1.017)</td><td align="left" colspan="1" rowspan="1">0.235</td></tr><tr><td align="left" colspan="1" rowspan="1">SRS</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">565/834</td><td align="left" colspan="1" rowspan="1">0.716 (0.636, 0.790)</td><td align="left" colspan="1" rowspan="1">81.6%</td><td align="left" colspan="1" rowspan="1">0.732 (0.691, 0.775)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="7" rowspan="1">3-year OS</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">530/539</td><td align="left" colspan="1" rowspan="1">0.996 (0.978, 1.000)</td><td align="left" colspan="1" rowspan="1">47.1%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-SRS</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">266/269</td><td align="left" colspan="1" rowspan="1">0.998 (0.983, 1.000)</td><td align="left" colspan="1" rowspan="1">7.5%</td><td align="left" colspan="1" rowspan="1">1.006 (0.989, 1.023)</td><td align="left" colspan="1" rowspan="1">0.539</td></tr><tr><td align="left" colspan="1" rowspan="1">SRS</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">494/514</td><td align="left" colspan="1" rowspan="1">0.975 (0.947, 0.994)</td><td align="left" colspan="1" rowspan="1">42.0%</td><td align="left" colspan="1" rowspan="1">0.977 (0.957, 0.998)</td><td align="left" colspan="1" rowspan="1">0.028</td></tr><tr><td align="left" colspan="7" rowspan="1">5-year OS</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">323/327</td><td align="left" colspan="1" rowspan="1">0.999 (0.979, 1.000)</td><td align="left" colspan="1" rowspan="1">36.6%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-SRS</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">519/536</td><td align="left" colspan="1" rowspan="1">0.979 (0.960, 0.993)</td><td align="left" colspan="1" rowspan="1">14.1%</td><td align="left" colspan="1" rowspan="1">0.980 (0.961, 1.000)</td><td align="left" colspan="1" rowspan="1">0.072</td></tr><tr><td align="left" colspan="1" rowspan="1">SRS</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">784/850</td><td align="left" colspan="1" rowspan="1">0.931 (0.902, 0.956)</td><td align="left" colspan="1" rowspan="1">44.8%</td><td align="left" colspan="1" rowspan="1">0.934 (0.913, 0.955)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="7" rowspan="1">3-year LC</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">402/413</td><td align="left" colspan="1" rowspan="1">0.988 (0.964, 1.000)</td><td align="left" colspan="1" rowspan="1">34.1%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-SRS</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">358/378</td><td align="left" colspan="1" rowspan="1">0.961 (0.925, 0.987)</td><td align="left" colspan="1" rowspan="1">39.4%</td><td align="left" colspan="1" rowspan="1">0.973 (0.946, 1.001)</td><td align="left" colspan="1" rowspan="1">0.057</td></tr><tr><td align="left" colspan="1" rowspan="1">SRS</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">129/159</td><td align="left" colspan="1" rowspan="1">0.814 (0.747, 0.872)</td><td align="left" colspan="1" rowspan="1">0%</td><td align="left" colspan="1" rowspan="1">0.834 (0.772, 0.900)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="7" rowspan="1">5-year LC</td></tr><tr><td align="left" colspan="1" rowspan="1">Proton therapy</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">342/374</td><td align="left" colspan="1" rowspan="1">0.927 (0.882, 0.963)</td><td align="left" colspan="1" rowspan="1">40.1%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-SRS</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">431/481</td><td align="left" colspan="1" rowspan="1">0.916 (0.851, 0.965)</td><td align="left" colspan="1" rowspan="1">76.2%</td><td align="left" colspan="1" rowspan="1">0.980 (0.938, 1.023)</td><td align="left" colspan="1" rowspan="1">0.365</td></tr><tr><td align="left" colspan="1" rowspan="1">SRS</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">361/524</td><td align="left" colspan="1" rowspan="1">0.686 (0.634, 0.736)</td><td align="left" colspan="1" rowspan="1">30.1%</td><td align="left" colspan="1" rowspan="1">0.753 (0.706, 0.804)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>An I&#178; &#8805; 50% suggests high heterogeneity across studies</p><p>PFS&#8201;=&#8201;progression-free survival; OS&#8201;=&#8201;overall survival; LC&#8201;=&#8201;local control; CI&#8201;=&#8201;confidence interval, SRS&#8201;=&#8201;stereotactic radiotherapy surgery, non-SRS&#8201;=&#8201;photon therapy other than SRS</p><p>The <italic toggle="yes">p</italic> value represents the difference between treatments</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par25">Despite its histologically benign nature and absence of metastatic potential, CP frequently progresses after treatment, necessitating lifelong surveillance and intervention. This poses substantial challenges to both healthcare systems and patients, underscoring the need for therapeutic strategies that optimize long-term disease control while minimizing morbidity. Since the late 1950s, radiotherapy has served as an indispensable adjuvant modality, playing a pivotal role in controlling tumor progression and reducing the risk of recurrence [<xref ref-type="bibr" rid="CR61">61</xref>]. However, the meticulous balance between efficacy and long-term toxicity is a central concern for neurosurgeons and radiation oncologists. Prior to the present study, several reviews addressing the efficacy of proton therapy and photon therapy were published [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Nonetheless, the hypothesis that proton therapy surpasses photon therapy has not been thoroughly validated [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. This study is the first to comprehensively review and pool the efficacy and safety of proton and photon therapy in mixed-age CP patients. The results revealed that the theoretical advantages of proton therapy in CPs may be real. Pooled analyses demonstrated statistically significant improvements in survival and disease control outcomes for proton therapy, including 3-year PFS, 5-year PFS, 5-year OS, 3-year LC, and 5-year LC. The absence of a statistically significant difference in 3-year OS between the two groups may be related to the benign nature of CPs.</p><p id="Par26">The toxic effects associated with proton and photon therapy remain a subject of debate. De Roeck et al. [<xref ref-type="bibr" rid="CR64">64</xref>] reported that one of the main clinical benefits of proton therapy is expected to improve neurocognitive outcomes. Bishop et al. [<xref ref-type="bibr" rid="CR18">18</xref>] showed that no differences in the incidence of radiotherapy toxicity between patients treated with proton therapy and those treated with intensity modulated radiation therapy (IMRT). However, Li et al. [<xref ref-type="bibr" rid="CR62">62</xref>] demonstrated that proton therapy has a lower risk of toxicity than photon therapy. In fact, our results suggested that proton therapy not only mitigates cognitive decline but also significantly reduces the risk of toxic effects across multiple domains, including visual, neurological, and miscellaneous toxicities. This favorable toxicity profile may be attributed to the intrinsic physical advantages of proton therapy, which delivers conformal radiation doses to complex tumor geometries while sparing adjacent organs at risk (e.g., hypothalamus and optic pathways), thereby reducing late toxicity and secondary functional deficits. Nonetheless, the endocrine toxicity findings indicated that photon therapy outperforms proton therapy. No definitive explanation can be offered for this observation at present, necessitating further research to elucidate this phenomenon.</p><p id="Par27">Photon therapy, encompassing SRS and conventional radiation therapy (non-SRS), represents a primary option for the adjuvant treatment of CP [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. The analysis of baseline characteristics revealed apparent dosimetric disparities between proton and photon therapy, primarily driven by the low-dose regimens employed in the SRS subgroup of photon therapy. Therefore, patients receiving photon therapy were divided into non-SRS and SRS groups in the study to allow comparison of the survival outcomes with those of patients receiving proton therapy. Except for the 3-year OS, other survival outcomes in the proton therapy cohort were superior to those in the non-SRS group, although no significant differences were observed. In contrast, proton therapy was superior to SRS (a lower dose) in all aspects of survival outcomes, which may be attributable to the physical advantages and biological superiority of proton therapy. These findings are indirectly supported by the study conducted by Yoo et al. [<xref ref-type="bibr" rid="CR66">66</xref>]. Their study indicates that non-SRS achieved better long-term PFS rates compared to SRS in the management of CP. Therefore, we believe that proton therapy should be the first choice for CP radiotherapy, followed by conventional radiation therapy, while SRS does not appear to be a routine treatment option. SRS may be more suitable for small (maximum diameter&#8201;&lt;&#8201;3&#160;cm), well-defined, solid CPs that are located more than 3&#160;mm away from the optic pathway [<xref ref-type="bibr" rid="CR67">67</xref>]. The optic nerves are highly sensitive to elevated daily doses of radiation, which limits the ability to fully treat the area with SRS but allows safe administration of the full dose with fractionated treatment using photons or protons.</p><p id="Par28">SRS delivers highly focused, high-dose radiation to a target area, often in a single session or a few fractions. Non-SRS and proton therapy involve delivering lower doses of radiation over a longer period (several weeks). Due to the proximity of CPs to critical structures such as the optic nerve/chiasm and hypothalamus, single or hypofractionated SRS treatment often struggles to achieve tumoricidal doses. This is because reducing the prescribed dose&#8212;typically necessary for safety near these structures&#8212;can lead to suboptimal tumor coverage [<xref ref-type="bibr" rid="CR68">68</xref>]. In SRS, the treatment is often focused on the small tumor remnant, which typically consists of the visible portion of the tumor on imaging [<xref ref-type="bibr" rid="CR69">69</xref>]. This approach tends to prioritize targeting the residual tumor or nodules rather than addressing the entire surgical cavity or the potential areas of microscopic tumor infiltration, which are often located at the periphery of the tumor bed. As a result, these potential areas are not always adequately treated, leading to the possibility of tumor recurrence at the edges of the treated volume [<xref ref-type="bibr" rid="CR70">70</xref>]. The superior survival outcomes of non-SRS and proton therapy may be attributed to the target volume encompassing the entire tumor bed. In contrast, the target volume in SRS only includes the residual tumor, which could potentially increase the occurrence of marginal failure. It is important to note that outcomes can vary depending on the specific cancer type, location, and individual patient factors.</p><p id="Par29">The dose of SRS is constrained in the management of CPs, mainly because of its proximity to the visual apparatus and hypothalamic-pituitary axis [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. By contrast, both proton therapy and non-SRS typically deliver higher total doses than SRS. Insufficient coverage of the target area largely accounts for the inferior tumor control observed with SRS. Importantly, the advantage of proton therapy over non-SRS photons does not stem from systematic dose escalation&#8212;indeed, our analysis showed comparable prescribed doses between the two modalities&#8212;but rather from its superior dose distribution, which permits better sparing of surrounding critical structures [<xref ref-type="bibr" rid="CR71">71</xref>]. In addition, a single high-dose irradiation of SRS may not be effective in killing hypoxic tumor cells, whereas the fractionated irradiation and potentially variable RBE of proton therapy may be more effective in controlling such cell subsets [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. The findings of this study suggested that the efficacy of proton therapy can be improved through dose escalation when the control treatment is dose deficient. When the dose is equivalent, the advantage is reflected mainly in organ protection. Moreover, the outcomes of subgroup analyses based on age were congruent with those obtained without group differentiation, demonstrating that proton therapy is predominantly more effective than photon therapy in both children and adults. Proton therapy may be associated with improved long-term survival and that the radiobiological benefit of proton therapy may be achieved primarily through reduced long-term toxicity rather than early tumor control.</p><p id="Par30">Our findings provide robust evidence supporting the clinical superiority of proton therapy in the multidisciplinary management of CP. Furthermore, our study emphasizes the need for continued comprehensive recording of outcomes from the increasing number of institutions delivering proton therapy. Subsequent investigations of proton treatment should be structured to obtain more comprehensive outcomes (both clinician-reported and patient-reported), especially concerning late effects, quality of life, functionality, and cost-effectiveness. Photon therapy has evolved from traditional 2D therapy to advanced IMRT and volumetric-modulated arc therapy. Technological advances have also been made in proton therapy, including moving from passive scattering to the use of an active scanning beam [<xref ref-type="bibr" rid="CR74">74</xref>]. However, it has to be acknowledged that proton therapy is used only in a limited number of centers, which restrict its availability as a first-line radiotherapy modality for patients with CPs. The limited access to proton therapy in many regions may pose a challenge to its widespread adoption and application in clinical practice. Conducting prospective trials to determine optimal radiotherapy is necessary because of heterogeneity and confounding factors. As more patients are treated with advanced radiotherapy with a prospective collection of outcomes, determination of whether outcomes are better with one therapy than with another may be possible.</p><sec id="Sec18"><title>Limitations</title><p id="Par31">The present study had some limitations. Most studies included in the analysis were observational studies from multiple global regions, exhibiting a fraction of heterogeneity, including variation in quality. Consequently, our analyses may have bias and confounding effects due to the attributes of the included studies. However, in the absence of randomized trials, a meta-analysis of observational studies is one of the few methods for evaluating efficacy and safety, and it follows the recommendation that all pertinent studies should be considered [<xref ref-type="bibr" rid="CR75">75</xref>]. Moreover, the follow-up time in the proton therapy cohort was generally shorter than that in the photon therapy cohort, perhaps resulting in an inadequate observation of long-term toxic events. Finally, certain outcomes, such as cognitive function, are often evaluated using different measurement tools or subjective assessments, while vision may be additionally affected by tumor-related compression before treatment. These factors may contribute to heterogeneity and introduce bias, underscoring the need for prospective studies with consistent reporting standards.</p></sec></sec><sec id="Sec19"><title>Conclusion</title><p id="Par32">This meta-analysis compared the efficacy and safety of proton and photon therapy in patients with CP. The outcomes suggest that proton therapy may be associated with improved survival outcomes and reduced toxic effects. In addition, the present findings suggest that non-SRS may lead to better survival outcomes than SRS in the management of CPs. Further studies are still needed to validate the advantages of proton therapy versus photon therapy for CP.</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11102_2025_1578_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Lai-Sheng Pan and Jing Zhang are contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank Prof. Peng Huang for his assistance with statistical analysis.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed to the study conception and design. Formal analysis and investigation: J.Z., YT.X., JB.Z.; Writing - original draft preparation: LS.P., J.Z.; Writing - review and editing: QY.W., T.H.; Resources: T.H.; Funding acquisition: T.H., LS.P; Supervision: QY.W., T.H. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (82360611), the Science and Technology Plan Project of Health Commission of Jiangxi Province (2023ZD002) and the Postgraduate Project of Jiangxi Society for Science Education (2025KXJYS256).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par33">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haupt</surname><given-names>R</given-names></name><name name-style="western"><surname>Magnani</surname><given-names>C</given-names></name><name name-style="western"><surname>Pavanello</surname><given-names>M</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>S</given-names></name><name name-style="western"><surname>Dama</surname><given-names>E</given-names></name><name name-style="western"><surname>Garr&#232;</surname><given-names>ML</given-names></name></person-group><article-title>Epidemiological aspects of craniopharyngioma</article-title><source>J Pediatr Endocrinol Metab Apr</source><year>2006</year><volume>19</volume><issue>Suppl 1</issue><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">16700303</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Haupt R, Magnani C, Pavanello M, Caruso S, Dama E, Garr&#232; ML (2006) Epidemiological aspects of craniopharyngioma. J Pediatr Endocrinol Metab Apr 19(Suppl 1):289&#8211;293<pub-id pub-id-type="pmid">16700303</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>EH</given-names></name><name name-style="western"><surname>Feldt-Rasmussen</surname><given-names>U</given-names></name><name name-style="western"><surname>Poulsgaard</surname><given-names>L</given-names></name><etal/></person-group><article-title>Incidence of craniopharyngioma in Denmark (n&#8201;=&#8201;189) and estimated world incidence of craniopharyngioma in children and adults</article-title><source>J Neurooncol</source><year>2011</year><volume>104</volume><issue>3</issue><fpage>755</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1007/s11060-011-0540-6</pub-id><pub-id pub-id-type="pmid">21336771</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Nielsen EH, Feldt-Rasmussen U, Poulsgaard L et al (2011) Incidence of craniopharyngioma in Denmark (n&#8201;=&#8201;189) and estimated world incidence of craniopharyngioma in children and adults. J Neurooncol 104(3):755&#8211;763. 10.1007/s11060-011-0540-6<pub-id pub-id-type="pmid">21336771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-011-0540-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louis</surname><given-names>DN</given-names></name><name name-style="western"><surname>Perry</surname><given-names>A</given-names></name><name name-style="western"><surname>Reifenberger</surname><given-names>G</given-names></name><etal/></person-group><article-title>The 2016 World Health Organization classification of tumors of the central nervous system: a summary</article-title><source>Acta Neuropathol</source><year>2016</year><volume>131</volume><issue>6</issue><fpage>803</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1007/s00401-016-1545-1</pub-id><pub-id pub-id-type="pmid">27157931</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803&#8211;820. 10.1007/s00401-016-1545-1<pub-id pub-id-type="pmid">27157931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-016-1545-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puget</surname><given-names>S</given-names></name><name name-style="western"><surname>Garnett</surname><given-names>M</given-names></name><name name-style="western"><surname>Wray</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement</article-title><source>J Neurosurg</source><year>2007</year><volume>106</volume><issue>1 Suppl</issue><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.3171/ped.2007.106.1.3</pub-id><pub-id pub-id-type="pmid">17233305</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Puget S, Garnett M, Wray A et al (2007) Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg 106(1 Suppl):3&#8211;12. 10.3171/ped.2007.106.1.3<pub-id pub-id-type="pmid">17233305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/ped.2007.106.1.3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ya&#351;argil</surname><given-names>MG</given-names></name><name name-style="western"><surname>Curcic</surname><given-names>M</given-names></name><name name-style="western"><surname>Kis</surname><given-names>M</given-names></name><name name-style="western"><surname>Siegenthaler</surname><given-names>G</given-names></name><name name-style="western"><surname>Teddy</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Roth</surname><given-names>P</given-names></name></person-group><article-title>Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients</article-title><source>J Neurosurg Jul</source><year>1990</year><volume>73</volume><issue>1</issue><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.3171/jns.1990.73.1.0003</pub-id><pub-id pub-id-type="pmid">2352020</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ya&#351;argil MG, Curcic M, Kis M, Siegenthaler G, Teddy PJ, Roth P (1990) Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg Jul 73(1):3&#8211;11. 10.3171/jns.1990.73.1.0003<pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/jns.1990.73.1.0003</pub-id><pub-id pub-id-type="pmid">2352020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>RL</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>LB</given-names></name><etal/></person-group><article-title>Comparative effectiveness of treatment options for pediatric craniopharyngiomas</article-title><source>J Neurosurg Pediatr Feb</source><year>2014</year><volume>13</volume><issue>2</issue><fpage>178</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.3171/2013.11.Peds1320</pub-id><pub-id pub-id-type="pmid">24313659</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Ali ZS, Bailey RL, Daniels LB et al (2014) Comparative effectiveness of treatment options for pediatric craniopharyngiomas. J Neurosurg Pediatr Feb 13(2):178&#8211;188. 10.3171/2013.11.Peds1320<pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2013.11.PEDS1320</pub-id><pub-id pub-id-type="pmid">24313659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Feng</surname><given-names>M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>F</given-names></name></person-group><article-title>Comparing survival outcomes of gross total resection and subtotal resection with radiotherapy for craniopharyngioma: a meta-analysis</article-title><source>J Surg Res</source><year>2018</year><volume>226</volume><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2018.01.029</pub-id><pub-id pub-id-type="pmid">29661278</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wang G, Zhang X, Feng M, Guo F (2018) Comparing survival outcomes of gross total resection and subtotal resection with radiotherapy for craniopharyngioma: a meta-analysis. J Surg Res 226:131&#8211;139. 10.1016/j.jss.2018.01.029<pub-id pub-id-type="pmid">29661278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jss.2018.01.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>M</given-names></name><name name-style="western"><surname>Delaney</surname><given-names>A</given-names></name><name name-style="western"><surname>Jurbergs</surname><given-names>N</given-names></name><etal/></person-group><article-title>Radiotherapy alone for pediatric patients with craniopharyngioma</article-title><source>J Neurooncol Jan</source><year>2022</year><volume>156</volume><issue>1</issue><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1007/s11060-021-03908-2</pub-id><pub-id pub-id-type="pmid">34846639</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Young M, Delaney A, Jurbergs N et al (2022) Radiotherapy alone for pediatric patients with craniopharyngioma. J Neurooncol Jan 156(1):195&#8211;204. 10.1007/s11060-021-03908-2<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-021-03908-2</pub-id><pub-id pub-id-type="pmid">34846639</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Boehling NS, Grosshans DR, Bluett JB et al (2012) Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas. Int J Radiat Oncol Biol Phys. 10.1016/j.ijrobp.2010.11.027<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2010.11.027</pub-id><pub-id pub-id-type="pmid">21277111</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Paganetti H, Niemierko A, Ancukiewicz M et al (2002) Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 10.1016/s0360-3016(02)02754-2<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0360-3016(02)02754-2</pub-id><pub-id pub-id-type="pmid">12023146</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><etal/></person-group><article-title>Proton beam therapy for craniopharyngioma: a systematic review and meta-analysis</article-title><source>Radiat Oncol Nov</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>161</fpage><pub-id pub-id-type="doi">10.1186/s13014-024-02556-w</pub-id><pub-id pub-id-type="pmcid">PMC11566716</pub-id><pub-id pub-id-type="pmid">39543740</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Li Z, Li Q, Tian H et al (2024) Proton beam therapy for craniopharyngioma: a systematic review and meta-analysis. Radiat Oncol Nov 14(1):161. 10.1186/s13014-024-02556-w<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13014-024-02556-w</pub-id><pub-id pub-id-type="pmcid">PMC11566716</pub-id><pub-id pub-id-type="pmid">39543740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Liberati</surname><given-names>A</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title><source>BMJ</source><year>2009</year><volume>339</volume><fpage>b2535</fpage><pub-id pub-id-type="doi">10.1136/bmj.b2535</pub-id><pub-id pub-id-type="pmid">19622551</pub-id><pub-id pub-id-type="pmcid">PMC2714657</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. 10.1136/bmj.b2535<pub-id pub-id-type="pmid">19622551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.b2535</pub-id><pub-id pub-id-type="pmcid">PMC2714657</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Wells GA SB, O&#8217;Connell D et al The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta analyses. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ohri.ca/programs/clinical_epidemiology/oxford.aspWells">https://www.ohri.ca/programs/clinical_epidemiology/oxford.aspWells</ext-link></mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DerSimonian</surname><given-names>R</given-names></name><name name-style="western"><surname>Laird</surname><given-names>N</given-names></name></person-group><article-title>Meta-analysis in clinical trials</article-title><source>Control Clin Trials</source><year>1986</year><volume>7</volume><issue>3</issue><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/0197-2456(86)90046-2</pub-id><pub-id pub-id-type="pmid">3802833</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177&#8211;188. 10.1016/0197-2456(86)90046-2<pub-id pub-id-type="pmid">3802833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0197-2456(86)90046-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T (2013) Meta-analysis of prevalence. J Epidemiol Community Health. 10.1136/jech-2013-203104<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jech-2013-203104</pub-id><pub-id pub-id-type="pmid">23963506</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>SG</given-names></name><name name-style="western"><surname>Deeks</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>Bmj Sep</source><year>2003</year><volume>6</volume><issue>7414</issue><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id><pub-id pub-id-type="pmcid">PMC192859</pub-id><pub-id pub-id-type="pmid">12958120</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Bmj Sep 6(7414):557&#8211;560. 10.1136/bmj.327.7414.557<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.327.7414.557</pub-id><pub-id pub-id-type="pmcid">PMC192859</pub-id><pub-id pub-id-type="pmid">12958120</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>M</given-names></name><name name-style="western"><surname>Minder</surname><given-names>C</given-names></name></person-group><article-title>Bias in meta-analysis detected by a simple, graphical test</article-title><source>Bmj Sep</source><year>1997</year><volume>13</volume><issue>7109</issue><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1136/bmj.315.7109.629</pub-id><pub-id pub-id-type="pmcid">PMC2127453</pub-id><pub-id pub-id-type="pmid">9310563</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj Sep 13(7109):629&#8211;634. 10.1136/bmj.315.7109.629<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.315.7109.629</pub-id><pub-id pub-id-type="pmcid">PMC2127453</pub-id><pub-id pub-id-type="pmid">9310563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Bishop AJ, Greenfield B, Mahajan A et al (2014) Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys. 10.1016/j.ijrobp.2014.05.051<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2014.05.051</pub-id><pub-id pub-id-type="pmcid">PMC4194252</pub-id><pub-id pub-id-type="pmid">25052561</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Friedrich C, Boekhoff S, Sowithayasakul P et al (2022) Treatment of childhood-onset craniopharyngioma patients using proton beam therapy versus photon-based radiation therapy in the prospective kraniopharyngeom 2007 trial. Conference proceeding. Neuro-oncology 24:i11. 10.1093/neuonc/noac079.034</mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merchant</surname><given-names>TE</given-names></name><name name-style="western"><surname>Hoehn</surname><given-names>ME</given-names></name><name name-style="western"><surname>Khan</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR) a single arm, phase 2 study</article-title><source>Lancet Oncol</source><year>2023</year><volume>24</volume><issue>5</issue><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/s1470-2045(23)00146-8</pub-id><pub-id pub-id-type="pmid">37084748</pub-id><pub-id pub-id-type="pmcid">PMC10408380</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Merchant TE, Hoehn ME, Khan RB et al (2023) Proton therapy and limited surgery for paediatric and adolescent patients with craniopharyngioma (RT2CR) a single arm, phase 2 study. Lancet Oncol 24(5):523&#8211;534. 10.1016/s1470-2045(23)00146-8<pub-id pub-id-type="pmid">37084748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(23)00146-8</pub-id><pub-id pub-id-type="pmcid">PMC10408380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravindra</surname><given-names>VM</given-names></name><name name-style="western"><surname>Okcu</surname><given-names>MF</given-names></name><name name-style="western"><surname>Ruggieri</surname><given-names>L</given-names></name><etal/></person-group><article-title>Comparison of multimodal surgical and radiation treatment methods for pediatric craniopharyngioma: long-term analysis of progression-free survival and morbidity</article-title><source>J Neurosurg Pediatr</source><year>2021</year><volume>28</volume><issue>2</issue><fpage>152</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.3171/2020.11.Peds20803</pub-id><pub-id pub-id-type="pmid">34049281</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ravindra VM, Okcu MF, Ruggieri L et al (2021) Comparison of multimodal surgical and radiation treatment methods for pediatric craniopharyngioma: long-term analysis of progression-free survival and morbidity. J Neurosurg Pediatr 28(2):152&#8211;159. 10.3171/2020.11.Peds20803<pub-id pub-id-type="pmid">34049281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2020.11.PEDS20803</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Ajithkumar T, Mazhari AL, Stickan-Verfuerth M et al (May 2018) Proton therapy for Craniopharyngioma - An early report from a single European centre. Article. Clinical oncology. 30(5):307&#8211;316. 10.1016/j.clon.2018.01.012<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clon.2018.01.012</pub-id><pub-id pub-id-type="pmid">29459099</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Beddok A, Scher N, Alapetite C et al (2023) Proton therapy for adult craniopharyngioma: experience of a single institution in 91 consecutive patients. Neuro Oncol. 10.1093/neuonc/noac210<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/neuonc/noac210</pub-id><pub-id pub-id-type="pmcid">PMC10076942</pub-id><pub-id pub-id-type="pmid">36002321</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Bischoff M, Khalil DA, Frisch S et al (2024) Outcome after modern proton beam therapy in childhood craniopharyngioma: results of the prospective registry study KiProReg. Int J Radiat Oncol Biol Phys. 10.1016/j.ijrobp.2024.03.015<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2024.03.015</pub-id><pub-id pub-id-type="pmid">38492813</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Del Baldo G, Vennarini S, Cacchione A et al (2022) Multidisciplinary management of craniopharyngiomas in children: a single center experience. Diagnostics (Basel). 10.3390/diagnostics12112745<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics12112745</pub-id><pub-id pub-id-type="pmcid">PMC9689811</pub-id><pub-id pub-id-type="pmid">36359587</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Indelicato</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sandler</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Clinical outcomes following proton therapy for children with central nervous system tumors referred overseas</article-title><source>Pediatr Blood Cancer</source><year>2017</year><pub-id pub-id-type="doi">10.1002/pbc.26654</pub-id><pub-id pub-id-type="pmid">28544746</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Indelicato DJ, Bradley JA, Sandler ES et al (2017) Clinical outcomes following proton therapy for children with central nervous system tumors referred overseas. Pediatr Blood Cancer. 10.1002/pbc.26654<pub-id pub-id-type="pmid">28544746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pbc.26654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Jimenez RB, Ahmed S, Johnson A et al (2021) Proton radiation therapy for pediatric craniopharyngioma. Int J Radiat Oncol Biol Phys. 10.1016/j.ijrobp.2021.02.045<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2021.02.045</pub-id><pub-id pub-id-type="pmid">33662460</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luu</surname><given-names>QT</given-names></name><name name-style="western"><surname>Loredo</surname><given-names>LN</given-names></name><name name-style="western"><surname>Archambeau</surname><given-names>JO</given-names></name><name name-style="western"><surname>Yonemoto</surname><given-names>LT</given-names></name><name name-style="western"><surname>Slater</surname><given-names>JM</given-names></name><name name-style="western"><surname>Slater</surname><given-names>JD</given-names></name></person-group><article-title>Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report</article-title><source>Cancer J</source><year>2006</year><volume>12</volume><issue>2</issue><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">16630407</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Luu QT, Loredo LN, Archambeau JO, Yonemoto LT, Slater JM, Slater JD (2006) Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J 12(2):155&#8211;159<pub-id pub-id-type="pmid">16630407</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rutenberg</surname><given-names>MS</given-names></name><name name-style="western"><surname>Rotondo</surname><given-names>RL</given-names></name><name name-style="western"><surname>Rao</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical outcomes following proton therapy for adult craniopharyngioma: a single-institution cohort study</article-title><source>J Neurooncol</source><year>2020</year><volume>147</volume><issue>2</issue><fpage>387</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1007/s11060-020-03432-9</pub-id><pub-id pub-id-type="pmid">32086697</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Rutenberg MS, Rotondo RL, Rao D et al (2020) Clinical outcomes following proton therapy for adult craniopharyngioma: a single-institution cohort study. J Neurooncol 147(2):387&#8211;395. 10.1007/s11060-020-03432-9<pub-id pub-id-type="pmid">32086697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-020-03432-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scher</surname><given-names>N</given-names></name><name name-style="western"><surname>Bentahila</surname><given-names>G</given-names></name><name name-style="western"><surname>Beddok</surname><given-names>A</given-names></name><etal/></person-group><article-title>Proton therapy for adult craniopharyngioma</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2021</year><volume>111</volume><issue>3S</issue><fpage>e561</fpage><lpage>e561</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2021.07.1518</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Scher N, Bentahila G, Beddok A et al (2021) Proton therapy for adult craniopharyngioma. Int J Radiat Oncol Biol Phys 111(3S):e561&#8211;e561. 10.1016/j.ijrobp.2021.07.1518</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>S</given-names></name><name name-style="western"><surname>Lim</surname><given-names>PS</given-names></name><name name-style="western"><surname>Bojaxhiu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Clinical outcomes and quality of life in children and adolescents with primary brain tumors treated with pencil beam scanning proton therapy</article-title><source>Pediatr Blood Cancer</source><year>2020</year><volume>67</volume><issue>12</issue><fpage>e28465</fpage><pub-id pub-id-type="doi">10.1002/pbc.28465</pub-id><pub-id pub-id-type="pmid">32902137</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Tran S, Lim PS, Bojaxhiu B et al (2020) Clinical outcomes and quality of life in children and adolescents with primary brain tumors treated with pencil beam scanning proton therapy. Pediatr Blood Cancer 67(12):e28465. 10.1002/pbc.28465<pub-id pub-id-type="pmid">32902137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pbc.28465</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Astradsson</surname><given-names>A</given-names></name><name name-style="western"><surname>af Rosenschold</surname><given-names>PM</given-names></name><name name-style="western"><surname>Feldt-Rasmussen</surname><given-names>U</given-names></name><etal/></person-group><article-title>Visual outcome, endocrine function and tumor control after fractionated stereotactic radiation therapy of craniopharyngiomas in adults: findings in a prospective cohort</article-title><source>Article Acta Oncol 2017</source><year>2017</year><volume>56</volume><issue>3</issue><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1080/0284186x.2016.1270466</pub-id><pub-id pub-id-type="pmid">28084862</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Astradsson A, af Rosenschold PM, Feldt-Rasmussen U et al (2017) Visual outcome, endocrine function and tumor control after fractionated stereotactic radiation therapy of craniopharyngiomas in adults: findings in a prospective cohort. Article Acta Oncol 2017 56(3):415&#8211;421. 10.1080/0284186x.2016.1270466<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/0284186X.2016.1270466</pub-id><pub-id pub-id-type="pmid">28084862</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Combs</surname><given-names>SE</given-names></name><name name-style="western"><surname>Thilmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Huber</surname><given-names>PE</given-names></name><name name-style="western"><surname>Hoess</surname><given-names>A</given-names></name><name name-style="western"><surname>Debus</surname><given-names>J</given-names></name><name name-style="western"><surname>Schulz-Ertner</surname><given-names>D</given-names></name></person-group><article-title>Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy</article-title><source>Cancer Jun</source><year>2007</year><volume>1</volume><issue>11</issue><fpage>2308</fpage><lpage>2314</lpage><pub-id pub-id-type="doi">10.1002/cncr.22703</pub-id><pub-id pub-id-type="pmid">17469176</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Combs SE, Thilmann C, Huber PE, Hoess A, Debus J, Schulz-Ertner D (2007) Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer Jun 1(11):2308&#8211;2314. 10.1002/cncr.22703<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.22703</pub-id><pub-id pub-id-type="pmid">17469176</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dho</surname><given-names>YS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Optimal strategy of gamma knife radiosurgery for craniopharyngiomas</article-title><source>J Neurooncol</source><year>2018</year><volume>140</volume><issue>1</issue><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1007/s11060-018-2943-0</pub-id><pub-id pub-id-type="pmid">29987747</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Dho YS, Kim YH, Kim JW et al (2018) Optimal strategy of gamma knife radiosurgery for craniopharyngiomas. J Neurooncol 140(1):135&#8211;143. 10.1007/s11060-018-2943-0<pub-id pub-id-type="pmid">29987747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-018-2943-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenfield</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Okcu</surname><given-names>MF</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma</article-title><source>Radiother Oncol</source><year>2015</year><volume>114</volume><issue>2</issue><fpage>224</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2014.11.035</pub-id><pub-id pub-id-type="pmid">25542650</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Greenfield BJ, Okcu MF, Baxter PA et al (2015) Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma. Radiother Oncol 114(2):224&#8211;229. 10.1016/j.radonc.2014.11.035<pub-id pub-id-type="pmid">25542650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.radonc.2014.11.035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>D</given-names></name><name name-style="western"><surname>Kedia</surname><given-names>S</given-names></name><name name-style="western"><surname>Kale</surname><given-names>SS</given-names></name></person-group><article-title>Should post-operative stereotactic radiosurgery be the standard of care in craniopharyngioma patients?</article-title><source>World Neurosurgery: X</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.wnsx.2024.100327</pub-id><pub-id pub-id-type="pmid">38455244</pub-id><pub-id pub-id-type="pmcid">PMC10918274</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Gupta S, Agrawal D, Kedia S, Kale SS (2024) Should post-operative stereotactic radiosurgery be the standard of care in craniopharyngioma patients? World Neurosurgery: X. 10.1016/j.wnsx.2024.100327<pub-id pub-id-type="pmid">38455244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wnsx.2024.100327</pub-id><pub-id pub-id-type="pmcid">PMC10918274</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrabi</surname><given-names>SB</given-names></name><name name-style="western"><surname>Adeberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Welzel</surname><given-names>T</given-names></name><etal/></person-group><article-title>Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: maximal tumor control with minimal side effects</article-title><source>Radiat Oncol Sep 16</source><year>2014</year><volume>9</volume><fpage>203</fpage><pub-id pub-id-type="doi">10.1186/1748-717x-9-203</pub-id><pub-id pub-id-type="pmcid">PMC4261584</pub-id><pub-id pub-id-type="pmid">25227427</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Harrabi SB, Adeberg S, Welzel T et al (2014) Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: maximal tumor control with minimal side effects. Radiat Oncol Sep 16 9:203. 10.1186/1748-717x-9-203<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1748-717X-9-203</pub-id><pub-id pub-id-type="pmcid">PMC4261584</pub-id><pub-id pub-id-type="pmid">25227427</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kida</surname><given-names>Y</given-names></name></person-group><article-title>Tolerance of the optic apparatus in single-fraction irradiation using stereotactic radiosurgery: evaluation in 100 patients with craniopharyngioma</article-title><source>Neurosurg Apr</source><year>2010</year><volume>66</volume><issue>4</issue><fpage>688</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1227/01.Neu.0000367554.96981.26</pub-id><pub-id pub-id-type="pmid">20190668</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Hasegawa T, Kobayashi T, Kida Y (2010) Tolerance of the optic apparatus in single-fraction irradiation using stereotactic radiosurgery: evaluation in 100 patients with craniopharyngioma. Neurosurg Apr 66(4):688&#8211;694 discussion 694-5. 10.1227/01.Neu.0000367554.96981.26<pub-id pub-id-type="doi" assigning-authority="pmc">10.1227/01.NEU.0000367554.96981.26</pub-id><pub-id pub-id-type="pmid">20190668</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashizume</surname><given-names>C</given-names></name><name name-style="western"><surname>Mori</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Shibamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nagai</surname><given-names>A</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>N</given-names></name></person-group><article-title>Stereotactic radiotherapy using novalis for craniopharyngioma adjacent to optic pathways</article-title><source>J Neurooncol Jun</source><year>2010</year><volume>98</volume><issue>2</issue><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1007/s11060-010-0180-2</pub-id><pub-id pub-id-type="pmid">20422439</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Hashizume C, Mori Y, Kobayashi T, Shibamoto Y, Nagai A, Hayashi N (2010) Stereotactic radiotherapy using novalis for craniopharyngioma adjacent to optic pathways. J Neurooncol Jun 98(2):239&#8211;247. 10.1007/s11060-010-0180-2<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-010-0180-2</pub-id><pub-id pub-id-type="pmid">20422439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwata</surname><given-names>H</given-names></name><name name-style="western"><surname>Tatewaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>M</given-names></name><etal/></person-group><article-title>Single and hypofractionated stereotactic radiotherapy with cyberknife for craniopharyngioma</article-title><source>J Neurooncol</source><year>2012</year><volume>106</volume><issue>3</issue><fpage>571</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1007/s11060-011-0693-3</pub-id><pub-id pub-id-type="pmid">21861196</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Iwata H, Tatewaki K, Inoue M et al (2012) Single and hypofractionated stereotactic radiotherapy with cyberknife for craniopharyngioma. J Neurooncol 106(3):571&#8211;577. 10.1007/s11060-011-0693-3<pub-id pub-id-type="pmid">21861196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-011-0693-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeon</surname><given-names>C</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Shin</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>The therapeutic efficacy of fractionated radiotherapy and gamma-knife radiosurgery for craniopharyngiomas</article-title><source>J Clin Neurosci Dec</source><year>2011</year><volume>18</volume><issue>12</issue><fpage>1621</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2011.03.028</pub-id><pub-id pub-id-type="pmid">22015100</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Jeon C, Kim S, Shin HJ et al (2011) The therapeutic efficacy of fractionated radiotherapy and gamma-knife radiosurgery for craniopharyngiomas. J Clin Neurosci Dec 18(12):1621&#8211;1625. 10.1016/j.jocn.2011.03.028<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jocn.2011.03.028</pub-id><pub-id pub-id-type="pmid">22015100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klimo</surname><given-names>P</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Venable</surname><given-names>GT</given-names></name><name name-style="western"><surname>Boop</surname><given-names>FA</given-names></name><name name-style="western"><surname>Merchant</surname><given-names>TE</given-names></name></person-group><article-title>Recurrent craniopharyngioma after conformal radiation in children and the burden of treatment</article-title><source>J Neurosurg Pediatr</source><year>2015</year><volume>15</volume><issue>5</issue><fpage>499</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.3171/2014.10.Peds14384</pub-id><pub-id pub-id-type="pmid">25700121</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Klimo P Jr., Venable GT, Boop FA, Merchant TE (2015) Recurrent craniopharyngioma after conformal radiation in children and the burden of treatment. J Neurosurg Pediatr 15(5):499&#8211;505. 10.3171/2014.10.Peds14384<pub-id pub-id-type="pmid">25700121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2014.10.PEDS14384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kida</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mori</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>T</given-names></name></person-group><article-title>Long-term results of gamma knife surgery for the treatment of craniopharyngioma in 98 consecutive cases</article-title><source>J Neurosurg</source><year>2005</year><volume>103</volume><issue>6</issue><fpage>482</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.3171/ped.2005.103.6.0482</pub-id><pub-id pub-id-type="pmid">16383245</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kobayashi T, Kida Y, Mori Y, Hasegawa T (2005) Long-term results of gamma knife surgery for the treatment of craniopharyngioma in 98 consecutive cases. J Neurosurg 103(6):482&#8211;488. 10.3171/ped.2005.103.6.0482<pub-id pub-id-type="pmid">16383245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/ped.2005.103.6.0482</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsugawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Hatano</surname><given-names>M</given-names></name><name name-style="western"><surname>Hashizume</surname><given-names>C</given-names></name><name name-style="western"><surname>Mori</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shibamoto</surname><given-names>Y</given-names></name></person-group><article-title>Gamma knife radiosurgery of craniopharyngioma: results of 30 cases treated at Nagoya radiosurgery center</article-title><source>Article Nagoya J Med Sci Aug</source><year>2015</year><volume>77</volume><issue>3</issue><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="pmcid">PMC4574332</pub-id><pub-id pub-id-type="pmid">26412891</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Kobayashi T, Tsugawa T, Hatano M, Hashizume C, Mori Y, Shibamoto Y (2015) Gamma knife radiosurgery of craniopharyngioma: results of 30 cases treated at Nagoya radiosurgery center. Article Nagoya J Med Sci Aug 77(3):447&#8211;454<pub-id pub-id-type="pmcid">PMC4574332</pub-id><pub-id pub-id-type="pmid">26412891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H-C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C-J</given-names></name><etal/></person-group><article-title>Gamma knife surgery for craniopharyngioma: report on a 20-year experience</article-title><source>J Neurosurg</source><year>2014</year><volume>121</volume><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.3171/2014.8.Gks141411</pub-id><pub-id pub-id-type="pmid">25434950</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Lee C-C, Yang H-C, Chen C-J et al (2014) Gamma knife surgery for craniopharyngioma: report on a 20-year experience. J Neurosurg 121:167&#8211;178. 10.3171/2014.8.Gks141411<pub-id pub-id-type="pmid">25434950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2014.8.GKS141411</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>RC</given-names></name><name name-style="western"><surname>Tovar</surname><given-names>I</given-names></name><name name-style="western"><surname>del Moral</surname><given-names>R</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>RC</given-names></name></person-group><article-title>PO-135 fractionated stereotactic radiotherapy (FSR) for craniopharyngiomas</article-title><source>Article Radiotherapy Oncol</source><year>2019</year><volume>141</volume><fpage>S57</fpage><pub-id pub-id-type="doi">10.1016/S0167-8140(20)30477-1</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Lopez RC, Tovar I, del Moral R, Lopez RC (2019) PO-135 fractionated stereotactic radiotherapy (FSR) for craniopharyngiomas. Article Radiotherapy Oncol 141:S57. 10.1016/S0167-8140(20)30477-1</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Losa</surname><given-names>M</given-names></name><name name-style="western"><surname>Pieri</surname><given-names>V</given-names></name><name name-style="western"><surname>Bailo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Single fraction and multisession gamma knife radiosurgery for craniopharyngioma</article-title><source>Pituitary</source><year>2018</year><volume>21</volume><issue>5</issue><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1007/s11102-018-0903-5</pub-id><pub-id pub-id-type="pmid">30043097</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Losa M, Pieri V, Bailo M et al (2018) Single fraction and multisession gamma knife radiosurgery for craniopharyngioma. Pituitary 21(5):499&#8211;506. 10.1007/s11102-018-0903-5<pub-id pub-id-type="pmid">30043097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11102-018-0903-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maranzano</surname><given-names>E</given-names></name><name name-style="western"><surname>Trippa</surname><given-names>F</given-names></name><name name-style="western"><surname>Casale</surname><given-names>M</given-names></name><etal/></person-group><article-title>Stereotactic fractionated radiotherapy for post-surgery progressive or recurrent craniopharyngioma</article-title><source>J Radiat Oncol</source><year>2013</year><volume>2</volume><issue>4</issue><fpage>401</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1007/s13566-012-0072-5</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Maranzano E, Trippa F, Casale M et al (2013) Stereotactic fractionated radiotherapy for post-surgery progressive or recurrent craniopharyngioma. J Radiat Oncol 2(4):401&#8211;406. 10.1007/s13566-012-0072-5</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minniti</surname><given-names>G</given-names></name><name name-style="western"><surname>Saran</surname><given-names>F</given-names></name><name name-style="western"><surname>Traish</surname><given-names>D</given-names></name><etal/></person-group><article-title>Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas</article-title><source>Radiother Oncol</source><year>2007</year><volume>82</volume><issue>1</issue><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2006.11.005</pub-id><pub-id pub-id-type="pmid">17161483</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Minniti G, Saran F, Traish D et al (2007) Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. Radiother Oncol 82(1):90&#8211;95. 10.1016/j.radonc.2006.11.005<pub-id pub-id-type="pmid">17161483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.radonc.2006.11.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>IH</given-names></name><name name-style="western"><surname>Park</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Early adjuvant radiotherapy toward long-term survival and better quality of life for craniopharyngiomas - a study in single institute</article-title><source>Childs Nerv Syst</source><year>2005</year><volume>21</volume><issue>8&#8211;9</issue><fpage>799</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1007/s00381-005-1189-2</pub-id><pub-id pub-id-type="pmid">15959734</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Moon SH, Kim IH, Park SW et al (2005) Early adjuvant radiotherapy toward long-term survival and better quality of life for craniopharyngiomas - a study in single institute. Childs Nerv Syst 21(8&#8211;9):799&#8211;807. 10.1007/s00381-005-1189-2<pub-id pub-id-type="pmid">15959734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00381-005-1189-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Niranjan A, Kano H, Mathieu D, Kondziolka D, Flickinger JC, Lunsford LD (2010) Radiosurgery for craniopharyngioma. Int J Radiat Oncol Biol Phys. 10.1016/j.ijrobp.2009.07.1693<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2009.07.1693</pub-id><pub-id pub-id-type="pmid">20005637</pub-id></mixed-citation></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogino</surname><given-names>A</given-names></name><name name-style="western"><surname>Niranjan</surname><given-names>A</given-names></name><name name-style="western"><surname>Kano</surname><given-names>H</given-names></name><name name-style="western"><surname>Flickinger</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lunsford</surname><given-names>LD</given-names></name></person-group><article-title>Optimizing stereotactic radiosurgery in patients with recurrent or residual craniopharyngiomas</article-title><source>J Neurooncol</source><year>2021</year><volume>154</volume><issue>1</issue><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1007/s11060-021-03806-7</pub-id><pub-id pub-id-type="pmid">34286414</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Ogino A, Niranjan A, Kano H, Flickinger JC, Lunsford LD (2021) Optimizing stereotactic radiosurgery in patients with recurrent or residual craniopharyngiomas. J Neurooncol 154(1):113&#8211;120. 10.1007/s11060-021-03806-7<pub-id pub-id-type="pmid">34286414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-021-03806-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pikis</surname><given-names>S</given-names></name><name name-style="western"><surname>Mantziaris</surname><given-names>G</given-names></name><name name-style="western"><surname>Lavezzo</surname><given-names>K</given-names></name><name name-style="western"><surname>Dabhi</surname><given-names>N</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>J</given-names></name></person-group><article-title>Stereotactic radiosurgery for craniopharyngiomas</article-title><source>Acta Neurochir (Wien) Nov</source><year>2021</year><volume>163</volume><issue>11</issue><fpage>3201</fpage><lpage>3207</lpage><pub-id pub-id-type="doi">10.1007/s00701-021-04990-1</pub-id><pub-id pub-id-type="pmid">34518903</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Pikis S, Mantziaris G, Lavezzo K, Dabhi N, Sheehan J (2021) Stereotactic radiosurgery for craniopharyngiomas. Acta Neurochir (Wien) Nov 163(11):3201&#8211;3207. 10.1007/s00701-021-04990-1<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00701-021-04990-1</pub-id><pub-id pub-id-type="pmid">34518903</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Poiset SJ, Song A et al (2024) In Yoon H,. Long-Term Outcomes of Surgery and Radiation Treatment for Adult Patients with Craniopharyngioma. World Neurosurg 187:e852-e859. 10.1016/j.wneu.2024.04.177<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.wneu.2024.04.177</pub-id><pub-id pub-id-type="pmid">38719077</pub-id></mixed-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Samanci Y, Essibayi MA, Askeroglu MO, Budak M, Karak&#246;se F, Peker S (2023) Frameless hypofractionated gamma knife radiosurgery for residual or recurrent craniopharyngioma. Neurosurgery. 10.1227/neu.0000000000002382<pub-id pub-id-type="doi" assigning-authority="pmc">10.1227/neu.0000000000002382</pub-id><pub-id pub-id-type="pmid">36722947</pub-id></mixed-citation></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz- Ertner</surname><given-names>D</given-names></name><name name-style="western"><surname>Frank</surname><given-names>C</given-names></name><name name-style="western"><surname>Herfarth</surname><given-names>KK</given-names></name><name name-style="western"><surname>Rhein</surname><given-names>B</given-names></name><name name-style="western"><surname>Wannenmacher</surname><given-names>M</given-names></name><name name-style="western"><surname>Debus</surname><given-names>J</given-names></name></person-group><article-title>Fractionated stereotactic radiotherapy for craniopharyngiomas</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2002</year><volume>54</volume><issue>4</issue><fpage>1114</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1016/s0360-3016(02)03029-8</pub-id><pub-id pub-id-type="pmid">12419438</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Schulz-Ertner D, Frank C, Herfarth KK, Rhein B, Wannenmacher M, Debus J (2002) Fractionated stereotactic radiotherapy for craniopharyngiomas. Int J Radiat Oncol Biol Phys 54(4):1114&#8211;1120. 10.1016/s0360-3016(02)03029-8<pub-id pub-id-type="pmid">12419438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0360-3016(02)03029-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selch</surname><given-names>MT</given-names></name><name name-style="western"><surname>DeSalles</surname><given-names>AAF</given-names></name><name name-style="western"><surname>Wade</surname><given-names>M</given-names></name><etal/></person-group><article-title>Initial clinical results of stereotactic radiotherapy for the treatment of craniopharyngiomas</article-title><source>Technol Cancer Res Treat</source><year>2002</year><volume>1</volume><issue>1</issue><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1177/153303460200100107</pub-id><pub-id pub-id-type="pmid">12614177</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Selch MT, DeSalles AAF, Wade M et al (2002) Initial clinical results of stereotactic radiotherapy for the treatment of craniopharyngiomas. Technol Cancer Res Treat 1(1):51&#8211;59. 10.1177/153303460200100107<pub-id pub-id-type="pmid">12614177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/153303460200100107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinojima</surname><given-names>N</given-names></name><name name-style="western"><surname>Yano</surname><given-names>S</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>D</given-names></name><etal/></person-group><article-title>Long-term outcomes of multidisciplinary treatment combining surgery and stereotactic radiotherapy with novalis for craniopharyngioma</article-title><source>J Clin Neurosci</source><year>2024</year><volume>120</volume><fpage>138</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2024.01.002</pub-id><pub-id pub-id-type="pmid">38244528</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Shinojima N, Yano S, Uchida D et al (2024) Long-term outcomes of multidisciplinary treatment combining surgery and stereotactic radiotherapy with novalis for craniopharyngioma. J Clin Neurosci 120:138&#8211;146. 10.1016/j.jocn.2024.01.002<pub-id pub-id-type="pmid">38244528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jocn.2024.01.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsugawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Gamma knife surgery for residual or recurrent craniopharyngioma after surgical resection: A Multi-institutional retrospective study in Japan</article-title><source>Cureus Feb</source><year>2020</year><volume>12</volume><issue>2</issue><fpage>e6973</fpage><pub-id pub-id-type="doi">10.7759/cureus.6973</pub-id><pub-id pub-id-type="pmcid">PMC7075476</pub-id><pub-id pub-id-type="pmid">32201653</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Tsugawa T, Kobayashi T, Hasegawa T et al (2020) Gamma knife surgery for residual or recurrent craniopharyngioma after surgical resection: A Multi-institutional retrospective study in Japan. Cureus Feb 12(2):e6973. 10.7759/cureus.6973<pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.6973</pub-id><pub-id pub-id-type="pmcid">PMC7075476</pub-id><pub-id pub-id-type="pmid">32201653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yen</surname><given-names>C-P</given-names></name><name name-style="western"><surname>Schlesinger</surname><given-names>D</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>J</given-names></name></person-group><article-title>Outcomes of gamma knife surgery for craniopharyngiomas</article-title><source>J Neuro-Oncol</source><year>2011</year><volume>104</volume><issue>1</issue><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1007/s11060-010-0494-0</pub-id><pub-id pub-id-type="pmid">21153860</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Xu Z, Yen C-P, Schlesinger D, Sheehan J (2011) Outcomes of gamma knife surgery for craniopharyngiomas. J Neuro-Oncol 104(1):305&#8211;313. 10.1007/s11060-010-0494-0<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-010-0494-0</pub-id><pub-id pub-id-type="pmid">21153860</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Regine WF, Kramer S (1992) Pediatric craniopharyngiomas - long-term results of combined treatment with surgery and radiation. Article. International Journal of Radiation Oncology Biology Physics 24(4):611&#8211;617.&#160;10.1016/0360-3016(92)90705-m<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0360-3016(92)90705-m</pub-id><pub-id pub-id-type="pmid">1429082</pub-id></mixed-citation></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Axier</surname><given-names>A</given-names></name><etal/></person-group><article-title>Proton therapy for craniopharyngioma in adults: a protocol for systematic review and meta-analysis</article-title><source>BMJ Open</source><year>2021</year><volume>11</volume><issue>6</issue><fpage>e046043</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2020-046043</pub-id><pub-id pub-id-type="pmid">34078637</pub-id><pub-id pub-id-type="pmcid">PMC8173282</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Li P, Wang J, Axier A et al (2021) Proton therapy for craniopharyngioma in adults: a protocol for systematic review and meta-analysis. BMJ Open 11(6):e046043. 10.1136/bmjopen-2020-046043<pub-id pub-id-type="pmid">34078637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2020-046043</pub-id><pub-id pub-id-type="pmcid">PMC8173282</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sang</surname><given-names>Y</given-names></name></person-group><article-title>Radiation therapy for childhood-onset craniopharyngioma: systematic review and meta-analysis</article-title><source>J Neurooncol</source><year>2025</year><volume>172</volume><issue>1</issue><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1007/s11060-024-04914-w</pub-id><pub-id pub-id-type="pmid">39751704</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Miao Y, Wu D, Li Y, Ji Y, Sang Y (2025) Radiation therapy for childhood-onset craniopharyngioma: systematic review and meta-analysis. J Neurooncol 172(1):89&#8211;98. 10.1007/s11060-024-04914-w<pub-id pub-id-type="pmid">39751704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11060-024-04914-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Roeck</surname><given-names>L</given-names></name><name name-style="western"><surname>van der Weide</surname><given-names>HL</given-names></name><name name-style="western"><surname>Eekers</surname><given-names>DBP</given-names></name><etal/></person-group><article-title>The European particle therapy network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation</article-title><source>Radiother Oncol</source><year>2022</year><volume>168</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2022.01.018</pub-id><pub-id pub-id-type="pmid">35093408</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">De Roeck L, van der Weide HL, Eekers DBP et al (2022) The European particle therapy network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation. Radiother Oncol 168:241&#8211;249. 10.1016/j.radonc.2022.01.018<pub-id pub-id-type="pmid">35093408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.radonc.2022.01.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Milano MT, Grimm J, Soltys SG et al (2021) Single- and multi-fraction stereotactic radiosurgery dose tolerances of the optic pathways. Int J Radiat Oncol Biol Phys. 10.1016/j.ijrobp.2018.01.053<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2018.01.053</pub-id><pub-id pub-id-type="pmcid">PMC9479557</pub-id><pub-id pub-id-type="pmid">29534899</pub-id></mixed-citation></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Ham</surname><given-names>CH</given-names></name><name name-style="western"><surname>Roh</surname><given-names>H</given-names></name><etal/></person-group><article-title>Radiosurgery versus radiation therapy for long term local control rate of craniopharyngioma: a meta-analysis</article-title><source>Neurosurg Rev Jan</source><year>2025</year><volume>28</volume><issue>1</issue><fpage>93</fpage><pub-id pub-id-type="doi">10.1007/s10143-025-03238-1</pub-id><pub-id pub-id-type="pmid">39873790</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Yoo HJ, Ham CH, Roh H et al (2025) Radiosurgery versus radiation therapy for long term local control rate of craniopharyngioma: a meta-analysis. Neurosurg Rev Jan 28(1):93. 10.1007/s10143-025-03238-1<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10143-025-03238-1</pub-id><pub-id pub-id-type="pmid">39873790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kondziolka</surname><given-names>D</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SM</given-names></name><name name-style="western"><surname>Brunswick</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>JS</given-names></name></person-group><article-title>The biology of radiosurgery and its clinical applications for brain tumors</article-title><source>Neuro Oncol</source><year>2015</year><volume>17</volume><issue>1</issue><fpage>29</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nou284</pub-id><pub-id pub-id-type="pmid">25267803</pub-id><pub-id pub-id-type="pmcid">PMC4483054</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Kondziolka D, Shin SM, Brunswick A, Kim I, Silverman JS (2015) The biology of radiosurgery and its clinical applications for brain tumors. Neuro Oncol 17(1):29&#8211;44. 10.1093/neuonc/nou284<pub-id pub-id-type="pmid">25267803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/neuonc/nou284</pub-id><pub-id pub-id-type="pmcid">PMC4483054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamogawa</surname><given-names>M</given-names></name><name name-style="western"><surname>Shuto</surname><given-names>T</given-names></name><name name-style="western"><surname>Matsunaga</surname><given-names>S</given-names></name></person-group><article-title>Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery/ stereotactic radiotherapy or fractionated stereotactic radiotherapy</article-title><source>Surg Neurol Int</source><year>2022</year><volume>13</volume><fpage>563</fpage><pub-id pub-id-type="doi">10.25259/SNI_802_2022</pub-id><pub-id pub-id-type="pmid">36600746</pub-id><pub-id pub-id-type="pmcid">PMC9805634</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Kamogawa M, Shuto T, Matsunaga S (2022) Effects of two different radiotherapies for craniopharyngiomas using stereotactic radiosurgery/ stereotactic radiotherapy or fractionated stereotactic radiotherapy. Surg Neurol Int 13:563. 10.25259/SNI_802_2022<pub-id pub-id-type="pmid">36600746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.25259/SNI_802_2022</pub-id><pub-id pub-id-type="pmcid">PMC9805634</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Combs</surname><given-names>SE</given-names></name><name name-style="western"><surname>Baumert</surname><given-names>BG</given-names></name><name name-style="western"><surname>Bendszus</surname><given-names>M</given-names></name><etal/></person-group><article-title>ESTRO ACROP guideline for target volume delineation of skull base tumors</article-title><source>Radiother Oncol</source><year>2021</year><volume>156</volume><fpage>80</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2020.11.014</pub-id><pub-id pub-id-type="pmid">33309848</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Combs SE, Baumert BG, Bendszus M et al (2021) ESTRO ACROP guideline for target volume delineation of skull base tumors. Radiother Oncol 156:80&#8211;94. 10.1016/j.radonc.2020.11.014<pub-id pub-id-type="pmid">33309848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.radonc.2020.11.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>BM</given-names></name><name name-style="western"><surname>Cho</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Differences in treatment outcomes depending on the adjuvant treatment modality in craniopharyngioma</article-title><source>Yonsei Med J</source><year>2025</year><volume>66</volume><issue>3</issue><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.3349/ymj.2023.0566</pub-id><pub-id pub-id-type="pmid">39999989</pub-id><pub-id pub-id-type="pmcid">PMC11865873</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Lee BM, Cho J, Kim DS et al (2025) Differences in treatment outcomes depending on the adjuvant treatment modality in craniopharyngioma. Yonsei Med J 66(3):141&#8211;150. 10.3349/ymj.2023.0566<pub-id pub-id-type="pmid">39999989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3349/ymj.2023.0566</pub-id><pub-id pub-id-type="pmcid">PMC11865873</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheehan</surname><given-names>JP</given-names></name><name name-style="western"><surname>Starke</surname><given-names>RM</given-names></name><name name-style="western"><surname>Kano</surname><given-names>H</given-names></name><etal/></person-group><article-title>Gamma knife radiosurgery for sellar and parasellar meningiomas: a multicenter study</article-title><source>J Neurosurg</source><year>2014</year><volume>120</volume><issue>6</issue><fpage>1268</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.3171/2014.2.Jns13139</pub-id><pub-id pub-id-type="pmid">24678777</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Sheehan JP, Starke RM, Kano H et al (2014) Gamma knife radiosurgery for sellar and parasellar meningiomas: a multicenter study. J Neurosurg 120(6):1268&#8211;1277. 10.3171/2014.2.Jns13139<pub-id pub-id-type="pmid">24678777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3171/2014.2.JNS13139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pajonk</surname><given-names>F</given-names></name><name name-style="western"><surname>Vlashi</surname><given-names>E</given-names></name><name name-style="western"><surname>McBride</surname><given-names>WH</given-names></name></person-group><article-title>Radiation resistance of cancer stem cells: the 4 r&#8217;s of radiobiology revisited</article-title><source>Stem Cells</source><year>2010</year><volume>28</volume><issue>4</issue><fpage>639</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1002/stem.318</pub-id><pub-id pub-id-type="pmid">20135685</pub-id><pub-id pub-id-type="pmcid">PMC2940232</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Pajonk F, Vlashi E, McBride WH (2010) Radiation resistance of cancer stem cells: the 4 r&#8217;s of radiobiology revisited. Stem Cells 28(4):639&#8211;648. 10.1002/stem.318<pub-id pub-id-type="pmid">20135685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/stem.318</pub-id><pub-id pub-id-type="pmcid">PMC2940232</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trott</surname><given-names>KR</given-names></name></person-group><article-title>Experimental results and clinical implications of the four r&#8217;s in fractionated radiotherapy</article-title><source>Radiat Environ Biophys</source><year>1982</year><volume>20</volume><issue>3</issue><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1007/bf01325465</pub-id><pub-id pub-id-type="pmid">7051129</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Trott KR (1982) Experimental results and clinical implications of the four r&#8217;s in fractionated radiotherapy. Radiat Environ Biophys 20(3):159&#8211;170. 10.1007/bf01325465<pub-id pub-id-type="pmid">7051129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01325465</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>SH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wong</surname><given-names>WW</given-names></name><etal/></person-group><article-title>Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>9</issue><fpage>1027</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1016/s1470-2045(14)70268-2</pub-id><pub-id pub-id-type="pmid">24980873</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Patel SH, Wang Z, Wong WW et al (2014) Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. Lancet Oncol 15(9):1027&#8211;1038. 10.1016/s1470-2045(14)70268-2<pub-id pub-id-type="pmid">24980873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(14)70268-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stroup</surname><given-names>DF</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>JA</given-names></name><name name-style="western"><surname>Morton</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group</article-title><source>Jama Apr</source><year>2000</year><volume>19</volume><issue>15</issue><fpage>2008</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1001/jama.283.15.2008</pub-id><pub-id pub-id-type="pmid">10789670</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. Jama Apr 19(15):2008&#8211;2012. 10.1001/jama.283.15.2008<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.283.15.2008</pub-id><pub-id pub-id-type="pmid">10789670</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>